<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>HERCEPTIN- trastuzumab 
			 </strong><br>Genentech, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Herceptin safely and effectively. See full prescribing information for Herceptin.<br><br>HERCEPTIN<span class="Sup">®</span> (trastuzumab)<br>Intravenous Infusion<br>Initial U.S. Approval: 1998</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">CARDIOMYOPATHY</span>, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY</h1>
<h1 class="Warning"> See full prescribing information for complete boxed warning </h1>
<p class="Highlighta"><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span>: Herceptin can result in sub-clinical and clinical <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> manifesting as CHF, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue Herceptin for <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>. (<a href="#i4i_section_ID_warningscardiomyopathy">5.1</a>, <a href="#i4i_section_ID_dosemodifications">2.2</a>)</span></span> </p>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">Infusion reactions, Pulmonary toxicity: Discontinue Herceptin for <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span>, or <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">acute respiratory distress syndrome</span>. (<a href="#i4i_section_ID_warningsinfusionreactions">5.2</a>, <a href="#i4i_section_ID_warningspulmonarytoxicity">5.4</a>)</span></span> </p>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">Embryo-Fetal Toxicity:  Exposure to Herceptin during pregnancy can result in <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span>, in some cases complicated by <span class="product-label-link" type="condition" conceptid="4213884" conceptname="Congenital hypoplasia of lung">pulmonary hypoplasia</span> and neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  (<a href="#i4i_section_ID_warningsembryofetal">5.3</a>, <a href="#i4i_pregnancy_ID_pregnancy">8.1</a>, <a href="#S8.6">8.6</a>)</span></span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<a name="id_acd33b48-a360-4547-a025-f787ddbb31c8"></a><table width="100%">
<col align="left" valign="top" width="80%">
<col align="right" valign="top" width="20%">
<tbody class="Headless">
<tr>
<td align="left" valign="top">Dosage and Administration (<a href="#i4i_dosage_admin_ID_dosageandadministration">2</a>)</td>
<td align="right" valign="bottom">04/2015</td>
</tr>
<tr>
<td align="left" valign="top">Warnings and Precautions (<a href="#i4i_warnings_precautions_ID_warningsprecautions">5</a>)</td>
<td align="right" valign="bottom">04/2015</td>
</tr>
</tbody>
</table>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">CARDIOMYOPATHY</span>, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY</h1>
<h1 class="Warning"> See full prescribing information for complete boxed warning </h1>
<p class="Highlighta"><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span>: Herceptin can result in sub-clinical and clinical <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> manifesting as CHF, and decreased LVEF, with greatest risk when administered concurrently with anthracyclines. Evaluate cardiac function prior to and during treatment. Discontinue Herceptin for <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>. (<a href="#i4i_section_ID_warningscardiomyopathy">5.1</a>, <a href="#i4i_section_ID_dosemodifications">2.2</a>)</span></span> </p>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">Infusion reactions, Pulmonary toxicity: Discontinue Herceptin for <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span>, or <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">acute respiratory distress syndrome</span>. (<a href="#i4i_section_ID_warningsinfusionreactions">5.2</a>, <a href="#i4i_section_ID_warningspulmonarytoxicity">5.4</a>)</span></span> </p>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">Embryo-Fetal Toxicity:  Exposure to Herceptin during pregnancy can result in <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span>, in some cases complicated by <span class="product-label-link" type="condition" conceptid="4213884" conceptname="Congenital hypoplasia of lung">pulmonary hypoplasia</span> and neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  (<a href="#i4i_section_ID_warningsembryofetal">5.3</a>, <a href="#i4i_pregnancy_ID_pregnancy">8.1</a>, <a href="#S8.6">8.6</a>)</span></span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Herceptin is a HER2/neu receptor antagonist indicated for: </p>
<ul>
<li>the treatment of HER2 overexpressing breast cancer (<a href="#i4i_section_ID_indicationadjuvant">1.1</a>,<a href="#i4i_section_ID_indicationmetastatic">1.2</a>).</li>
<li>the treatment of HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma (<a href="#i4i_section_id_033431bc-4988-4189-af56-87d2fb5f64f6">1.3</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">For intravenous (IV) infusion only. Do not administer as an IV push or bolus (<a href="#i4i_section_ID_warningsinfusionreactions">5.2</a>).</span> </p>
<p class="Highlighta"><span class="Underline">Do not substitute Herceptin (trastuzumab) for or with ado-trastuzumab emtansine. (<a href="#i4i_section_ID_dosesschedules">2.1</a>)</span> </p>
<p class="Highlighta"><span class="Bold">Adjuvant Treatment of HER2-Overexpressing Breast Cancer</span> (<a href="#i4i_section_ID_dosesschedules">2.1</a>)  </p>
<p class="Highlighta">Administer at either: </p>
<ul>
<li>Initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks, or</li>
<li>Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30–90 minutes IV infusion every three weeks for 52 weeks.</li>
</ul>
<p class="Highlighta"><span class="Bold">Metastatic HER2-Overexpressing Breast Cancer</span> (<a href="#i4i_section_ID_dosesschedules">2.1</a>) </p>
<ul><li>Initial dose of 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of 2 mg/kg as 30 minute IV infusions.</li></ul>
<p class="Highlighta"><span class="Bold">Metastatic HER2-overexpressing Gastric Cancer</span> (<a href="#i4i_section_ID_dosesschedules">2.1</a>) </p>
<ul><li>Initial dose of 8 mg/kg over 90 minutes IV infusion, followed by 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks.</li></ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul><li>Multidose vial nominally containing 440 mg Herceptin as a lyophilized, sterile powder. (<a href="#i4i_dosage_form_strength_ID_dosageforms">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul><li>None. (<a href="#i4i_contraindications_ID_contraindications">4</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li>Exacerbation of Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> (<a href="#i4i_section_ID_exacerbationchemotherapyinducedneutropenia">5.5</a>, <a href="#i4i_section_ID_adversereactionsclincialtrials">6.1</a>)</li>
<li>HER2 testing should be performed using FDA-approved tests by laboratories with demonstrated proficiency. (<a href="#i4i_section_ID_warningsher2testing">5.6</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"><span class="Bold">Adjuvant Breast Cancer</span> </p>
<ul><li>Most common adverse reactions (≥ 5%) are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>. (<a href="#i4i_section_ID_adversereactionsclincialtrials">6.1</a>)</li></ul>
<p class="Highlighta"><span class="Bold">Metastatic Breast Cancer</span> </p>
<ul><li>Most common adverse reactions (≥ 10%) are <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. (<a href="#i4i_section_ID_adversereactionsclincialtrials">6.1</a>)</li></ul>
<p class="Highlighta"><span class="Bold">Metastatic Gastric Cancer</span> </p>
<ul><li>Most common adverse reactions (≥ 10%) are <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucosal inflammation</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, and <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>. (<a href="#i4i_section_ID_adversereactionsclincialtrials">6.1</a>)</li></ul>
<p class="Highlighta"><span class="Bold"><span class="Emphasis">To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span></span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Nursing Mothers:  Discontinue nursing or discontinue Herceptin. (<a href="#i4i_nursing_mothers_id_8c61e7a4-c680-4eba-9ea1-c7069e448f96">8.3</a>) </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 4/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">CARDIOMYOPATHY</span>, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Adjuvant Breast Cancer</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Metastatic Breast Cancer</a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Metastatic Gastric Cancer</a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Doses and Schedules</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Important Dosing Considerations</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Preparation for Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Infusion Reactions</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Embryo-Fetal Toxicity</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Pulmonary Toxicity</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Exacerbation of Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> </a></h2>
<h2><a href="#section-5.6" class="toc">5.6 HER2 Testing</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Immunogenicity</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6		Females of Reproductive Potential</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Adjuvant Breast Cancer</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Metastatic Breast Cancer</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Metastatic Gastric Cancer</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-14.1" class="toc">16.1 How Supplied</a></h2>
<h2><a href="#section-14.2" class="toc">16.2 Stability and Storage</a></h2>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="id_b641e93a-5973-4878-a5ec-04a065c9ff16"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">CARDIOMYOPATHY</span>, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY</h1>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span></span></p>
<p><span class="Bold">Herceptin administration can result in sub-clinical and clinical <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. The incidence and severity was highest in patients receiving Herceptin with anthracycline-containing chemotherapy regimens.</span></p>
<p><span class="Bold">Evaluate left ventricular function in all patients prior to and during treatment with Herceptin. Discontinue Herceptin treatment in patients receiving adjuvant therapy and withhold Herceptin in patients with <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span> for clinically significant decrease in left ventricular function. [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_ID_warningscardiomyopathy">5.1</a>) and Dosage and Administration (<a href="#i4i_section_ID_dosemodifications">2.2</a>)</span>]</span></p>
<p><span class="Bold">Infusion Reactions; Pulmonary Toxicity</span></p>
<p><span class="Bold">Herceptin administration can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of Herceptin administration. Interrupt Herceptin infusion for <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> or clinically significant <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. Monitor patients until symptoms completely resolve. Discontinue Herceptin for <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span>, or <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">acute respiratory distress syndrome</span>. [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_ID_warningsinfusionreactions">5.2</a>, <a href="#i4i_section_ID_warningspulmonarytoxicity">5.4)</a></span>]</span></p>
<p><span class="Bold">Embryo Fetal Toxicity</span></p>
<p><span class="Bold">Exposure to Herceptin during pregnancy can result in <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> and <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> sequence manifesting as <span class="product-label-link" type="condition" conceptid="4213884" conceptname="Congenital hypoplasia of lung">pulmonary hypoplasia</span>, skeletal abnormalities, and neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. [<span class="Italics">see Warnings and Precautions (<a href="#i4i_section_ID_warningsembryofetal">5.3</a>), Use in Specific Populations (<a href="#i4i_pregnancy_ID_pregnancy">8.1</a>)</span>]</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_ID_indicationsandusage"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_indicationadjuvant"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Adjuvant Breast Cancer</h2>
<p class="First">Herceptin is indicated for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature <span class="Italics">[see Clinical Studies (<a href="#i4i_clinical_studies_ID_clinicalstudies">14.1</a>)]</span>) breast cancer</p>
<ul>
<li>as part of a treatment regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel</li>
<li>with docetaxel and carboplatin</li>
<li>as a single agent following multi-modality anthracycline based therapy. </li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_indicationmetastatic"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Metastatic Breast Cancer</h2>
<p class="First">Herceptin is indicated:</p>
<ul>
<li> In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer </li>
<li>As a single agent for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_033431bc-4988-4189-af56-87d2fb5f64f6"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Metastatic Gastric Cancer</h2>
<p class="First">Herceptin is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_ID_dosageandadministration"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_dosesschedules"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Doses and Schedules</h2>
<ul class="Disc">
<li><span class="Bold">Do not administer as an intravenous push or bolus. Do not mix Herceptin with other drugs.</span></li>
<li><span class="Bold">Do not substitute Herceptin (trastuzumab) for or with ado-trastuzumab emtansine.</span></li>
</ul>
<p class="First"><span class="Italics">Adjuvant Treatment, Breast Cancer:</span></p>
<p>Administer according to one of the following doses and schedules for a total of 52 weeks of Herceptin therapy:</p>
<p>During and following paclitaxel, docetaxel, or docetaxel/carboplatin:</p>
<ul>
<li>Initial dose of 4 mg/kg as an intravenous infusion over 90 minutes then at 2 mg/kg as an intravenous infusion over 30 minutes weekly during chemotherapy for the first 12 weeks (paclitaxel or docetaxel) or 18 weeks (docetaxel/carboplatin).</li>
<li>One week following the last weekly dose of Herceptin, administer Herceptin at 6 mg/kg as an intravenous infusion over 30–90 minutes every three weeks.</li>
</ul>
<p>As a single agent within three weeks following completion of multi-modality, anthracycline-based chemotherapy regimens:</p>
<ul>
<li>Initial dose at 8 mg/kg as an intravenous infusion over 90 minutes</li>
<li>Subsequent doses at 6 mg/kg as an intravenous infusion over 30–90 minutes every three weeks.</li>
</ul>
<p><span class="Italics">[see Dosage and Administration (<a href="#i4i_section_ID_dosemodifications">2.2</a>)]</span></p>
<ul><li style="border-left:1px solid;"><span class="XmChange">Extending adjuvant treatment beyond one year is not recommended <span class="Italics">[see Adverse Reactions (<a href="#i4i_section_ID_adversereactionsclincialtrials">6.1</a>)]</span>.</span></li></ul>
<p><span class="Italics"> Metastatic Treatment, Breast Cancer:</span></p>
<ul><li>Administer Herceptin, alone or in combination with paclitaxel, at an initial dose of 4 mg/kg as a 90 minute intravenous infusion followed by subsequent once weekly doses of 2 mg/kg as 30 minute intravenous infusions until disease progression.</li></ul>
<p><span class="Italics">Metastatic Gastric Cancer:</span></p>
<ul><li>Administer Herceptin at an initial dose of 8 mg/kg as a 90 minute intravenous infusion followed by subsequent doses of 6 mg/kg as an intravenous infusion over 30-90 minutes every three weeks until disease progression <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_ID_dosemodifications">2.2</a>)].</span>
</li></ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_dosemodifications"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Important Dosing Considerations</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">If the patient has missed a dose of Herceptin by one week or less, then the usual maintenance dose (weekly schedule: 2 mg/kg; three-weekly schedule: 6 mg/kg) should be administered as soon as possible.  Do not wait until the next planned cycle.  Subsequent Herceptin maintenance doses should be administered 7 days or 21 days later according to the weekly or three-weekly schedules, respectively.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">If the patient has missed a dose of Herceptin by more than one week, a re-loading dose of Herceptin should be administered over approximately 90 minutes (weekly schedule: 4 mg/kg; three-weekly schedule: 8 mg/kg), as soon as possible.  Subsequent Herceptin maintenance doses (weekly schedule: 2 mg/kg; three-weekly schedule 6 mg/kg) should be administered 7 days or 21 days later according to the weekly or three-weekly schedules, respectively.</span></p>
<p><span class="Italics">Infusion Reactions</span></p>
<p><span class="Italics">[see <a href="#id_b641e93a-5973-4878-a5ec-04a065c9ff16">Boxed Warning</a>, Warnings and Precautions (<a href="#i4i_section_ID_warningsinfusionreactions">5.2</a>)]</span></p>
<ul>
<li>Decrease the rate of infusion for mild or moderate infusion reactions</li>
<li>Interrupt the infusion in patients with <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> or clinically significant <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span></li>
<li>Discontinue Herceptin for severe or life-threatening infusion reactions.</li>
</ul>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span></span></p>
<p><span class="Italics">[see <a href="#id_b641e93a-5973-4878-a5ec-04a065c9ff16">Boxed Warning</a>, Warnings and Precautions (<a href="#i4i_section_ID_warningscardiomyopathy">5.1</a>)]</span></p>
<p>Assess left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> (LVEF) prior to initiation of Herceptin and at regular intervals during treatment. Withhold Herceptin dosing for at least 4 weeks for either of the following:</p>
<ul>
<li>≥ 16% absolute decrease in LVEF from pre-treatment values</li>
<li>LVEF below institutional limits of normal and ≥ 10% absolute decrease in LVEF from pretreatment values.</li>
</ul>
<p>Herceptin may be resumed if, within 4–8 weeks, the LVEF returns to normal limits and the absolute decrease from baseline is ≤ 15%.</p>
<p>Permanently discontinue Herceptin for a persistent (&gt; 8 weeks) LVEF decline or for suspension of Herceptin dosing on more than 3 occasions for <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_prepforadmin"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Preparation for Administration</h2>
<p class="First">To prevent medication errors, it is important to check the vial labels to ensure that the drug being prepared and administered is Herceptin (trastuzumab) and not ado-trastuzumab emtansine.</p>
<p><span class="Italics">Reconstitution</span></p>
<p> Reconstitute each 440 mg vial of Herceptin with 20 mL of Bacteriostatic Water for Injection (BWFI), USP, containing 1.1% benzyl alcohol as a preservative to yield a multi-dose solution containing 21 mg/mL trastuzumab. In patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to benzyl alcohol, reconstitute with 20 mL of Sterile Water for Injection (SWFI) without preservative to yield a single use solution. </p>
<p>Use appropriate aseptic technique when performing the following reconstitution steps:</p>
<ul>
<li>Using a sterile syringe, slowly inject the 20 mL of diluent into the vial containing the lyophilized cake of Herceptin. The stream of diluent should be directed into the lyophilized cake.</li>
<li>Swirl the vial gently to aid reconstitution. <span class="Bold">DO NOT SHAKE.</span>
</li>
<li>Slight foaming of the product may be present upon reconstitution. Allow the vial to stand undisturbed for approximately 5 minutes.</li>
<li>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Inspect visually for particulates and discoloration. The solution should be free of visible particulates, clear to slightly opalescent and colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow.</li>
<li>
<span class="Underline">Store reconstituted Herceptin at 2–8° C;</span> discard unused Herceptin after 28 days. <span class="Underline">If Herceptin is reconstituted with SWFI</span> without preservative, use immediately and discard any unused portion.</li>
</ul>
<p><span class="Italics">Dilution</span></p>
<ul>
<li>Determine the dose (mg) of Herceptin <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_ID_dosesschedules">2.1</a>)]</span>. Calculate the volume of the 21 mg/mL reconstituted Herceptin solution needed, withdraw this amount from the vial and add it to an infusion bag containing 250 mL of 0.9% Sodium Chloride Injection, USP.<br><span class="Bold">DO NOT USE DEXTROSE (5%) SOLUTION.</span>
</li>
<li>Gently invert the bag to mix the solution.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_ID_dosageforms"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">440 mg lyophilized powder per multi-use vial.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_ID_contraindications"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_ID_warningsprecautions"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_warningscardiomyopathy"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span></h2>
<p class="First">Herceptin can cause left ventricular cardiac dysfunction, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, disabling <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, and cardiac <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> <span class="Italics">[see Boxed Warning:<a href="#id_b641e93a-5973-4878-a5ec-04a065c9ff16"> <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span></a>]</span>. Herceptin can also cause asymptomatic decline in left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> (LVEF).</p>
<p>There is a 4–6 fold increase in the incidence of symptomatic myocardial dysfunction among patients receiving Herceptin as a single agent or in combination therapy compared with those not receiving Herceptin. The highest absolute incidence occurs when Herceptin is administered with an anthracycline.</p>
<p>Withhold Herceptin for ≥ 16% absolute decrease in LVEF from pre-treatment values or an LVEF value below institutional limits of normal and ≥ 10% absolute decrease in LVEF from pretreatment values <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_ID_dosemodifications">2.2</a>)]</span>. The safety of continuation or resumption of Herceptin in patients with Herceptin-induced left ventricular cardiac dysfunction has not been studied.</p>
<p style="border-left:1px solid;"><span class="XmChange">Patients who receive anthracycline after stopping Herceptin may also be at increased risk of cardiac dysfunction <span class="Italics">[see <a href="#i4i_interactions_id_f08abdd5-54cf-42c0-abff-c6af91d6d346">Drug Interactions (7)</a></span> and <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</span></p>
<p><span class="Italics">Cardiac Monitoring</span></p>
<p>Conduct thorough cardiac assessment, including history, physical examination, and determination of LVEF by echocardiogram or MUGA scan. The following schedule is recommended:</p>
<ul>
<li>Baseline LVEF measurement immediately prior to initiation of Herceptin</li>
<li>LVEF measurements every 3 months during and upon completion of Herceptin</li>
<li>Repeat LVEF measurement at 4 week intervals if Herceptin is withheld for significant left ventricular cardiac dysfunction  <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_ID_dosemodifications">2.2</a>)]</span>
</li>
<li>LVEF measurements every 6 months for at least 2 years following completion of Herceptin as a component of adjuvant therapy.</li>
</ul>
<p>In Study 1, 15% (158/1031) of patients discontinued Herceptin due to clinical evidence of myocardial dysfunction or significant decline in LVEF after a median follow-up duration of 8.7 years in the AC-TH arm. In Study 3 (one-year Herceptin treatment), the number of patients who discontinued Herceptin due to cardiac toxicity at 12.6 months median duration of follow-up was 2.6% (44/1678). In Study 4, a total of 2.9% (31/1056) patients in the TCH arm (1.5% during the chemotherapy phase and 1.4% during the monotherapy phase) and 5.7% (61/1068) patients in the AC-TH arm (1.5% during the chemotherapy phase and 4.2% during the monotherapy phase) discontinued Herceptin due to cardiac toxicity.</p>
<p>Among 64 patients receiving adjuvant chemotherapy (Studies 1 and 2) who developed <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, one patient died of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, one patient died suddenly without documented etiology and 33 patients were receiving cardiac medication at last follow-up. Approximately 24% of the surviving patients had recovery to a normal LVEF (defined as ≥50%) and no symptoms on continuing medical management at the time of last follow-up. Incidence of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> is presented in<a href="#table1"> Table 1</a>. The safety of continuation or resumption of Herceptin in patients with Herceptin-induced left ventricular cardiac dysfunction has not been studied.</p>
<a name="table1"></a><table width="75%">
<caption><span> Table 1: Incidence of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> in Adjuvant Breast Cancer Studies</span></caption>
<col align="left" valign="top" width="10%">
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead>
<tr class="First">
<td class="Lrule Toprule" align="left" valign="top"></td>
<td class="Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Incidence of CHF</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center" valign="top">Study</td>
<td align="center" valign="top">Regimen</td>
<td align="center" valign="top">Herceptin</td>
<td class="Rrule" align="center" valign="top">Control</td>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Median follow-up duration for studies 1 and 2 combined was 8.3 years in the AC→TH arm.  </dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Anthracycline (doxorubicin) and cyclophosphamide.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Includes 1 patient with fatal <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> and 1 patient with <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span> without documented etiology.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>Includes NYHA II-IV and cardiac <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> at 12.6 months median duration of follow-up in the one-year Herceptin arm. </dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Toprule" align="left" valign="top">1 &amp; 2<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
<td class="Toprule" align="left" valign="top">AC<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a> → Paclitaxel+Herceptin</td>
<td align="center" valign="top"><span class="XmChange">3.2% (64/2000)<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a></span></td>
<td class="Rrule" align="center" valign="top">1.3% (21/1655)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">3<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td align="left" valign="top">Chemo → Herceptin</td>
<td align="center" valign="top">2% (30/1678)</td>
<td class="Rrule" align="center" valign="top">0.3% (5/1708)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">4</td>
<td align="left" valign="top">AC<a href="#footnote-2" class="Sup">†</a> → Docetaxel+Herceptin</td>
<td align="center" valign="top">2% (20/1068)</td>
<td class="Rrule" align="center" valign="top">0.3% (3/1050)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left" valign="top">4</td>
<td align="left" valign="top">Docetaxel+Carbo+Herceptin</td>
<td align="center" valign="top">0.4% (4/1056)</td>
<td class="Rrule" align="center" valign="top">0.3% (3/1050)</td>
</tr>
</tbody>
</table>
<p style="border-left:1px solid;"><span class="XmChange">In Study 3 (one-year Herceptin treatment), at a median follow-up duration of 8 years, the incidence of severe CHF (NYHA III &amp; IV) was 0.8%, and the rate of mild symptomatic and asymptomatic <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span> was 4.6%.</span></p>
<a name="table2"></a><table>
<caption><span> Table 2: Incidence of Cardiac Dysfunction<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a> in Metastatic Breast Cancer Studies</span></caption>
<col align="left" width="15%">
<col align="left" width="25%">
<col align="center" width="15%">
<col align="center" width="15%">
<col align="center" width="15%">
<col align="center" width="15%">
<thead>
<tr class="First">
<td class="Lrule Toprule" align="left" valign="top"> </td>
<td class="Toprule" align="left" valign="top"> </td>
<td class="Rrule" align="center" colspan="4" valign="top">Incidence</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td class="Botrule" align="center" colspan="2" valign="top">NYHA I-IV</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">NYHA III-IV</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center" valign="top">Study</td>
<td align="center" valign="top">Event</td>
<td align="center" valign="top">Herceptin</td>
<td align="center" valign="top">Control</td>
<td align="center" valign="top">Herceptin</td>
<td class="Rrule" align="center" valign="top">Control</td>
</tr>
</thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> or significant asymptomatic decrease in LVEF.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>Anthracycline (doxorubicin or epirubicin) and cyclophosphamide.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">‡</a></dt>
<dd>Includes 1 patient with fatal <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Toprule" align="left" valign="top">5 (AC)<a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a>
</td>
<td class="Toprule" align="left" valign="top">Cardiac Dysfunction</td>
<td class="Toprule" align="center" valign="top">28%</td>
<td class="Toprule" align="center" valign="top">7%</td>
<td class="Toprule" align="center" valign="top">19%</td>
<td class="Rrule" align="center" valign="top">3%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">5 (paclitaxel)</td>
<td align="left" valign="top">Cardiac Dysfunction</td>
<td align="center" valign="top">11%</td>
<td align="center" valign="top">1%</td>
<td align="center" valign="top">4%</td>
<td class="Rrule" align="center" valign="top">1%</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left" valign="top">6</td>
<td align="left" valign="top">Cardiac Dysfunction<a name="footnote-reference-7" href="#footnote-7" class="Sup">‡</a>
</td>
<td align="center" valign="top">7%</td>
<td align="center" valign="top">N/A</td>
<td align="center" valign="top">5%</td>
<td class="Rrule" align="center" valign="top">N/A</td>
</tr>
</tbody>
</table>
<p>In Study 4, the incidence of NCI-CTC Grade 3/4 <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">cardiac ischemia</span>/<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> was higher in the Herceptin containing regimens: (AC-TH: 0.3% (3/1068) and TCH 0.2% (2/1056)) as compared to none in AC-T.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_warningsinfusionreactions"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Infusion Reactions</h2>
<p class="First">Infusion reactions consist of a symptom complex characterized by <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, and on occasion included <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (in some cases at tumor sites), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>. <span class="Italics">[see Adverse Reactions (<a href="#i4i_section_ID_adversereactionsclincialtrials">6.1</a>)]</span></p>
<p>In postmarketing reports, serious and fatal infusion reactions have been reported. Severe reactions which include <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, and severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, were usually reported during or immediately following the initial infusion. However, the onset and clinical course were variable including progressive worsening, initial improvement followed by clinical deterioration, or delayed post-infusion events with rapid clinical deterioration. For fatal events, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> occurred within hours to days following a serious infusion reaction.</p>
<p>Interrupt Herceptin infusion in all patients experiencing <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, clinically significant <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and intervention of medical therapy administered, which may include: epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen. Patients should be evaluated and carefully monitored until complete resolution of signs and symptoms. Permanent discontinuation should be strongly considered in all patients with severe infusion reactions.</p>
<p>There are no data regarding the most appropriate method of identification of patients who may safely be retreated with Herceptin after experiencing a severe infusion reaction. Prior to resumption of Herceptin infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. While some patients tolerated Herceptin infusions, others had recurrent severe infusion reactions despite pre-medications.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_warningsembryofetal"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Embryo-Fetal Toxicity</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Herceptin can cause fetal harm when administered to a pregnant woman.  In post marketing reports, use of Herceptin during pregnancy resulted in cases of <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> and <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> sequence manifesting as <span class="product-label-link" type="condition" conceptid="4213884" conceptname="Congenital hypoplasia of lung">pulmonary hypoplasia</span>, skeletal abnormalities, and neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  If the patient becomes pregnant while taking Herceptin or within 7 months following the last dose of Herceptin, apprise the patient of the potential hazard to a fetus <span class="Italics">[see Use in Specific Populations (<a href="#i4i_pregnancy_ID_pregnancy">8.1</a>)]</span>.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Advise females of reproductive potential to avoid becoming pregnant while taking Herceptin.  If contraceptive methods are being considered, use effective contraception during treatment and for at least 7 months after receiving the last dose of Herceptin <span class="Italics"> [see <a href="#S8.6">Use in Specific Populations (8.6)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_warningspulmonarytoxicity"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Pulmonary Toxicity</h2>
<p class="First">Herceptin use can result in serious and fatal pulmonary toxicity. Pulmonary toxicity includes <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span>, pulmonary infiltrates, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusions</span>, non-cardiogenic <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, pulmonary insufficiency and <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">acute respiratory distress syndrome</span>, and <span class="product-label-link" type="condition" conceptid="4197819" conceptname="Fibrosis of lung">pulmonary fibrosis</span>. Such events can occur as sequelae of infusion reactions <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_ID_warningsinfusionreactions">5.2</a>)]</span>. Patients with symptomatic intrinsic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> or with extensive tumor involvement of the lungs, resulting in <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> at rest, appear to have more severe toxicity. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_exacerbationchemotherapyinducedneutropenia"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Exacerbation of Chemotherapy-Induced <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> </h2>
<p class="First">In randomized, controlled clinical trials the per-patient incidences of NCI CTC Grade 3–4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and of <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> were higher in patients receiving Herceptin in combination with myelosuppressive chemotherapy as compared to those who received chemotherapy alone. The incidence of septic <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was similar among patients who received Herceptin and those who did not. <span class="Italics">[see Adverse Reactions (<a href="#i4i_section_ID_adversereactionsclincialtrials">6.1</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_warningsher2testing"></a><a name="section-5.6"></a><p></p>
<h2>5.6 HER2 Testing</h2>
<p class="First">Detection of HER2 protein overexpression is necessary for selection of patients appropriate for Herceptin therapy because these are the only patients studied and for whom benefit has been shown. Due to differences in tumor histopathology, use FDA-approved tests for the specific tumor type (breast or gastric/gastroesophageal adenocarcinoma) to assess HER2 protein overexpression and HER2 gene amplification.  Tests should be performed by laboratories with demonstrated proficiency in the specific technology being utilized. Improper assay performance, including use of suboptimally fixed tissue, failure to utilize specified reagents, deviation from specific assay instructions, and failure to include appropriate controls for assay validation, can lead to unreliable results.</p>
<p>Several FDA-approved commercial assays are available to aid in the selection of breast cancer and metastatic gastric cancer patients for Herceptin therapy. Users should refer to the package inserts of specific assay kits for information on the Intended Use, and the validation and performance of each assay.</p>
<p>Limitations in assay precision make it inadvisable to rely on a single method to rule out potential Herceptin benefit.</p>
<p>Treatment outcomes for adjuvant breast cancer (Studies 2 and 3) and for metastatic breast cancer (Study 5) as a function of IHC and FISH testing are provided in <a href="#table8">Tables 8</a> and <a href="#table10">10</a>.</p>
<p>Assessment of HER2 protein overexpression and HER2 gene amplification in metastatic gastric cancer should be performed using FDA-approved tests specifically for gastric cancers due to differences in gastric vs. breast histopathology, including incomplete membrane staining and more frequent heterogeneous expression of HER2 seen in gastric cancers. Study 7 demonstrated that gene amplification and protein overexpression were not as well correlated as with breast cancer. Treatment outcomes for metastatic gastric cancer (Study 7), based on HER2 gene amplification (FISH) and HER2 protein overexpression (IHC) test results are provided in <a href="#table14">Table14</a>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_ID_adversereactions"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in greater detail in other sections of the label:</p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_ID_warningscardiomyopathy">5.1</a>)]</span>
</li>
<li>Infusion reactions <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_ID_warningsinfusionreactions">5.2</a>)]</span>
</li>
<li>Embryo-fetal Toxicity <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_ID_warningsembryofetal">5.3</a>)]</span>
</li>
<li>Pulmonary toxicity <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_ID_warningspulmonarytoxicity">5.4</a>)]</span>
</li>
<li>Exacerbation of chemotherapy-induced <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_ID_exacerbationchemotherapyinducedneutropenia">5.5</a>)]</span>
</li>
</ul>
<p>The most common adverse reactions in patients receiving Herceptin in the adjuvant and metastatic breast cancer setting are <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, infusion reactions, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, increased <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>. Adverse reactions requiring interruption or discontinuation of Herceptin treatment include CHF, significant decline in left ventricular cardiac function, severe infusion reactions, and pulmonary toxicity <span class="Italics">[see Dosage and Administration <a href="#i4i_section_ID_dosemodifications">(2.2)</a>]</span>.</p>
<p>In the metastatic gastric cancer setting, the most common adverse reactions (≥ 10%) that were increased (≥ 5% difference) in the Herceptin arm as compared to the chemotherapy alone arm were <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infections</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">mucosal inflammation</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, and <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>.  The most common adverse reactions which resulted in discontinuation of treatment on the Herceptin-containing arm in the absence of disease progression were <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_adversereactionsclincialtrials"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Italics">Adjuvant Breast Cancer Studies</span></p>
<p>The data below reflect exposure to one-year Herceptin therapy across three randomized, open-label studies, Studies 1, 2, and 3, with (n=3678) or without (n= 3363) trastuzumab in the adjuvant treatment of breast cancer.</p>
<p>The data summarized in<a href="#table3"> Table 3 </a>below, from Study 3, reflect exposure to Herceptin in 1678 patients; the median treatment duration was 51 weeks and median number of infusions was 18. Among the 3386 patients enrolled in the observation and one-year Herceptin arms of Study 3 at a median duration of follow-up of 12.6 months in the Herceptin arm, the median age was 49 years (range: 21 to 80 years), 83% of patients were Caucasian, and 13% were Asian.</p>
<a name="table3"></a><table>
<caption><span>Table 3: Adverse Reactions for Study 3<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a>, All Grades<a name="footnote-reference-9" href="#footnote-9" class="Sup">†</a></span></caption>
<col align="left" width="50%">
<col align="center" width="25%">
<col align="center" width="25%">
<thead>
<tr class="First">
<td class="Lrule Toprule" align="center" valign="top"></td>
<td class="Toprule" align="center" valign="top">One Year Herceptin</td>
<td class="Rrule" align="center" valign="top">Observation</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center" valign="top">Adverse Reaction</td>
<td align="center" valign="top">(n=1678)</td>
<td class="Rrule" align="center" valign="top">(n=1708)</td>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>Median follow-up duration of 12.6 months in the one-year Herceptin treatment arm.</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">†</a></dt>
<dd>The incidence of Grade 3 or higher adverse reactions was &lt;1% in both arms for each listed term.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">‡</a></dt>
<dd>Higher level grouping term.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Toprule" align="left" valign="top"><span class="Underline"><br>Cardiac </span></td>
<td class="Toprule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top"></td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td align="center" valign="top">64 (4%)</td>
<td class="Rrule" align="center" valign="top">35 (2%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center" valign="top">60 (4%)</td>
<td class="Rrule" align="center" valign="top">29 (2%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">Ejection Fraction</span> Decreased</td>
<td align="center" valign="top">58 (3.5%)</td>
<td class="Rrule" align="center" valign="top">11 (0.6%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></td>
<td align="center" valign="top">48 (3%)</td>
<td class="Rrule" align="center" valign="top">12 (0.7%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac Arrhythmias</span><a name="footnote-reference-10" href="#footnote-10" class="Sup">‡</a>
</td>
<td align="center" valign="top">40 (3%)</td>
<td class="Rrule" align="center" valign="top">17 (1%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Cardiac Failure Congestive</span></td>
<td align="center" valign="top">30 (2%)</td>
<td class="Rrule" align="center" valign="top">5 (0.3%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></td>
<td align="center" valign="top">9 (0.5%)</td>
<td class="Rrule" align="center" valign="top">4 (0.2%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorder</span></td>
<td align="center" valign="top">5 (0.3%)</td>
<td class="Rrule" align="center" valign="top">0 (0%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">Ventricular Dysfunction</td>
<td align="center" valign="top">4 (0.2%)</td>
<td class="Rrule" align="center" valign="top">0 (0%)</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="3" valign="top"><span class="Underline"><br>Respiratory Thoracic <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span> </span></td></tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td align="center" valign="top">81 (5%)</td>
<td class="Rrule" align="center" valign="top">34 (2%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></td>
<td align="center" valign="top">70 (4%)</td>
<td class="Rrule" align="center" valign="top">9 (0.5%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td align="center" valign="top">57 (3%)</td>
<td class="Rrule" align="center" valign="top">26 (2%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">URI</td>
<td align="center" valign="top">46 (3%)</td>
<td class="Rrule" align="center" valign="top">20 (1%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td align="center" valign="top">36 (2%)</td>
<td class="Rrule" align="center" valign="top">6 (0.4%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td align="center" valign="top">32 (2%)</td>
<td class="Rrule" align="center" valign="top">8 (0.5%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td align="center" valign="top">26 (2%)</td>
<td class="Rrule" align="center" valign="top">5 (0.3%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td align="center" valign="top">25 (2%)</td>
<td class="Rrule" align="center" valign="top">1 (0.06%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">Pulmonary Hypertension</span></td>
<td align="center" valign="top">4 (0.2%)</td>
<td class="Rrule" align="center" valign="top">0 (0%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial Pneumonitis</span></td>
<td align="center" valign="top">4 (0.2%)</td>
<td class="Rrule" align="center" valign="top">0 (0%)</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="3" valign="top">
<br><span class="Underline"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span> </span>
</td></tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center" valign="top">123 (7%)</td>
<td class="Rrule" align="center" valign="top">16 (1%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center" valign="top">108 (6%)</td>
<td class="Rrule" align="center" valign="top">19 (1%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center" valign="top">58 (3.5%)</td>
<td class="Rrule" align="center" valign="top">10 (0.6%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center" valign="top">33 (2%)</td>
<td class="Rrule" align="center" valign="top">17 (1%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center" valign="top">30 (2%)</td>
<td class="Rrule" align="center" valign="top">9 (0.5%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Upper Abdominal Pain</span></td>
<td align="center" valign="top">29 (2%)</td>
<td class="Rrule" align="center" valign="top">15 (1%)</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="3" valign="top"><span class="Underline"><br>Musculoskeletal &amp; <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span> </span></td></tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="center" valign="top">137 (8%)</td>
<td class="Rrule" align="center" valign="top">98 (6%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></td>
<td align="center" valign="top">91 (5%)</td>
<td class="Rrule" align="center" valign="top">58 (3%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td align="center" valign="top">63 (4%)</td>
<td class="Rrule" align="center" valign="top">17 (1%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone Pain</span></td>
<td align="center" valign="top">49 (3%)</td>
<td class="Rrule" align="center" valign="top">26 (2%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle Spasm</span></td>
<td align="center" valign="top">46 (3%)</td>
<td class="Rrule" align="center" valign="top">3 (0.2%)</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="3" valign="top">
<br><span class="Underline"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span> </span>
</td></tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center" valign="top">162 (10%)</td>
<td class="Rrule" align="center" valign="top">49 (3%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paraesthesia</span></td>
<td align="center" valign="top">29 (2%)</td>
<td class="Rrule" align="center" valign="top">11 (0.6%)</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="3" valign="top"><span class="Underline"><br>Skin &amp; Subcutaneous Tissue Disorders</span></td></tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center" valign="top">70 (4%)</td>
<td class="Rrule" align="center" valign="top">10 (0.6%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">Nail Disorders</span></td>
<td align="center" valign="top">43 (2%)</td>
<td class="Rrule" align="center" valign="top">0 (0%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td align="center" valign="top">40 (2%)</td>
<td class="Rrule" align="center" valign="top">10 (0.6%)</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="3" valign="top"><span class="Underline"><br>General disorders </span></td></tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td align="center" valign="top">100 (6%)</td>
<td class="Rrule" align="center" valign="top">6 (0.4%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema Peripheral</span></td>
<td align="center" valign="top">79 (5%)</td>
<td class="Rrule" align="center" valign="top">37 (2%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></td>
<td align="center" valign="top">85 (5%)</td>
<td class="Rrule" align="center" valign="top">0 (0%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">Aesthenia</td>
<td align="center" valign="top">75 (4.5%)</td>
<td class="Rrule" align="center" valign="top">30 (2%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like Illness</td>
<td align="center" valign="top">40 (2%)</td>
<td class="Rrule" align="center" valign="top">3 (0.2%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">Sudden Death</span> </td>
<td align="center" valign="top">1 (0.06%)</td>
<td class="Rrule" align="center" valign="top">0 (0%)</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="3" valign="top"><span class="Underline"><br><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> </span></td></tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td align="center" valign="top">135 (8%)</td>
<td class="Rrule" align="center" valign="top">43 (3%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">UTI</td>
<td align="center" valign="top">39 (3%)</td>
<td class="Rrule" align="center" valign="top">13 (0.8%)</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="3" valign="top">
<br><span class="Underline"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span>
</td></tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></td>
<td align="center" valign="top">10 (0.6%)</td>
<td class="Rrule" align="center" valign="top">1 (0.06%)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="135215" conceptname="Hashimoto thyroiditis">Autoimmune Thyroiditis</span></td>
<td align="center" valign="top">4 (0.3%)</td>
<td class="Rrule" align="center" valign="top">0 (0%)</td>
</tr>
</tbody>
</table>
<p>In Study 3, a comparison of 3-weekly Herceptin treatment for two years versus one year was also performed.  The rate of asymptomatic cardiac dysfunction was increased in the 2-year Herceptin treatment arm (8.1% versus 4.6% in the one-year Herceptin treatment arm).  More patients experienced at least one adverse reaction of grade 3 or higher in the 2-year Herceptin treatment arm (20.4%) compared with the one-year Herceptin treatment arm (16.3%).</p>
<p>The safety data from Studies 1 and 2 were obtained from 3655 patients, of whom 2000 received Herceptin; the median treatment duration was 51 weeks. The median age was 49 years (range: 24–80); 84% of patients were White, 7% Black, 4% Hispanic, and 3% Asian.</p>
<p>In Study 1, only Grade 3–5 adverse events, treatment-related Grade 2 events, and Grade 2–5 <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> were collected during and for up to 3 months following protocol-specified treatment. The following non-cardiac adverse reactions of Grade 2–5 occurred at an incidence of at least 2% greater among patients receiving Herceptin plus chemotherapy as compared to chemotherapy alone:  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (29.5% vs. 22.4%), <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (24.0% vs. 12.8%), <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span> (17.1% vs. 15.0%), <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (12.3% vs. 6.7%), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (11.8% vs. 4.6%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>/<span class="product-label-link" type="condition" conceptid="135029" conceptname="Peeling of skin">desquamation</span> (10.9% vs. 7.6%), <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (10.5% vs. 8.4%), <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (6.4% vs. 4.3%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (6.2% vs. 3.8%), <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (5.5% vs. 3.0%), <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (4.7% vs. 2.7%) and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (4.3% vs. 1.5%). The majority of these events were Grade 2 in severity.</p>
<p>In Study 2, data collection was limited to the following investigator-attributed treatment-related adverse reactions: NCI-CTC Grade 4 and 5 hematologic toxicities, Grade 3–5 non-hematologic toxicities, selected Grade 2–5 toxicities associated with taxanes (<span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgias</span>, <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail changes</span>, motor <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4318869" conceptname="Sensory neuropathy">sensory neuropathy</span>) and Grade 1–5 cardiac toxicities occurring during chemotherapy and/or Herceptin treatment. The following non-cardiac adverse reactions of Grade 2–5 occurred at an incidence of at least 2% greater among patients receiving Herceptin plus chemotherapy as compared to chemotherapy alone: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (12.2% vs. 9.1%), <span class="product-label-link" type="condition" conceptid="4211923" conceptname="Nail changes">nail changes</span> (11.5% vs.6.8%), <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (2.4% vs. 0.2%), and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2.2% vs. 0%). The majority of these events were Grade 2 in severity.</p>
<p>Safety data from Study 4 reflect exposure to Herceptin as part of an adjuvant treatment regimen from 2124 patients receiving at least one dose of study treatment [AC-TH: n = 1068; TCH: n = 1056]. The overall median treatment duration was 54 weeks in both the AC-TH and TCH arms. The median number of infusions was 26 in the AC-TH arm and 30 in the TCH arm, including weekly infusions during the chemotherapy phase and every three week dosing in the monotherapy period. Among these patients, the median age was 49 years (range 22 to 74 years). In Study 4, the toxicity profile was similar to that reported in Studies 1, 2, and 3 with the exception of a low incidence of CHF in the TCH arm.</p>
<p><span class="Italics">Metastatic Breast Cancer Studies</span></p>
<p>The data below reflect exposure to Herceptin in one randomized, open-label study, Study 5, of chemotherapy with (n=235) or without (n=234) trastuzumab in patients with metastatic breast cancer, and one single-arm study (Study 6; n=222) in patients with metastatic breast cancer. Data in<a href="#table4"> Table 4 </a>are based on Studies 5 and 6.</p>
<p>Among the 464 patients treated in Study 5, the median age was 52 years (range: 25–77 years). Eighty-nine percent were White, 5% Black, 1% Asian and 5% other racial/ethnic groups. All patients received 4 mg/kg initial dose of Herceptin followed by 2 mg/kg weekly. The percentages of patients who received Herceptin treatment for ≥ 6 months and ≥ 12 months were 58% and 9%, respectively.</p>
<p>Among the 352 patients treated in single agent studies (213 patients from Study 6), the median age was 50 years (range 28–86 years), 86% were White, 3% were Black, 3% were Asian, and 8% in other racial/ethnic groups. Most of the patients received 4 mg/kg initial dose of Herceptin followed by 2 mg/kg weekly. The percentages of patients who received Herceptin treatment for ≥ 6 months and ≥ 12 months were 31% and 16%, respectively.</p>
<a name="table4"></a><table>
<caption><span>Table 4: Per-Patient Incidence of Adverse Reactions Occurring in ≥5% of Patients in Uncontrolled Studies or at Increased Incidence in the Herceptin Arm (Studies 5 and 6)</span></caption>
<col align="left" width="40%">
<col align="center" width="10%">
<col align="center" width="10%">
<col align="center" width="10%">
<col align="center" width="10%">
<col align="center" width="10%">
<col align="center" width="10%">
<thead><tr class="First Last">
<td class="Botrule Lrule" align="left" valign="bottom"></td>
<td class="Botrule" align="left" valign="bottom">Single Agent<a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a> n = 352</td>
<td class="Botrule" align="left" valign="bottom">Herceptin + Paclitaxel<br> n = 91</td>
<td class="Botrule" align="left" valign="bottom">Paclitaxel Alone<br> n = 95</td>
<td class="Botrule" align="left" valign="bottom">Herceptin + AC<a name="footnote-reference-12" href="#footnote-12" class="Sup">†</a><br> n = 143</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="bottom">AC<a href="#footnote-12" class="Sup">†</a> Alone<br> n  =  135</td>
</tr></thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>Data for Herceptin single agent were from 4 studies, including 213 patients from Study 6.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">†</a></dt>
<dd>Anthracycline (doxorubicin or epirubicin) and cyclophosphamide.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Toprule" align="left" valign="top"><span class="Underline">Body as a Whole</span></td>
<td class="Toprule" align="left" valign="top"> </td>
<td class="Toprule" align="left" valign="top"> </td>
<td class="Toprule" align="left" valign="top"> </td>
<td class="Toprule" align="left" valign="top"> </td>
<td class="Rrule" align="left" colspan="2" valign="top"> </td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td align="left" valign="top">47%</td>
<td align="left" valign="top">61%</td>
<td align="left" valign="top">62%</td>
<td align="left" valign="top">57%</td>
<td class="Rrule" align="left" colspan="2" valign="top">42%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="left" valign="top">42%</td>
<td align="left" valign="top">62%</td>
<td align="left" valign="top">57%</td>
<td align="left" valign="top">54%</td>
<td class="Rrule" align="left" colspan="2" valign="top">55%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td align="left" valign="top">36%</td>
<td align="left" valign="top">49%</td>
<td align="left" valign="top">23%</td>
<td align="left" valign="top">56%</td>
<td class="Rrule" align="left" colspan="2" valign="top">34%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></td>
<td align="left" valign="top">32%</td>
<td align="left" valign="top">41%</td>
<td align="left" valign="top">4%</td>
<td align="left" valign="top">35%</td>
<td class="Rrule" align="left" colspan="2" valign="top">11%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="left" valign="top">26%</td>
<td align="left" valign="top">36%</td>
<td align="left" valign="top">28%</td>
<td align="left" valign="top">44%</td>
<td class="Rrule" align="left" colspan="2" valign="top">31%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td align="left" valign="top">22%</td>
<td align="left" valign="top">34%</td>
<td align="left" valign="top">22%</td>
<td align="left" valign="top">23%</td>
<td class="Rrule" align="left" colspan="2" valign="top">18%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td align="left" valign="top">22%</td>
<td align="left" valign="top">34%</td>
<td align="left" valign="top">30%</td>
<td align="left" valign="top">27%</td>
<td class="Rrule" align="left" colspan="2" valign="top">15%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td align="left" valign="top">20%</td>
<td align="left" valign="top">47%</td>
<td align="left" valign="top">27%</td>
<td align="left" valign="top">47%</td>
<td class="Rrule" align="left" colspan="2" valign="top">31%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Flu syndrome</span></td>
<td align="left" valign="top">10%</td>
<td align="left" valign="top">12%</td>
<td align="left" valign="top">5%</td>
<td align="left" valign="top">12%</td>
<td class="Rrule" align="left" colspan="2" valign="top">6%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental injury</span></td>
<td align="left" valign="top">6%</td>
<td align="left" valign="top">13%</td>
<td align="left" valign="top">3%</td>
<td align="left" valign="top">9%</td>
<td class="Rrule" align="left" colspan="2" valign="top">4%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span></td>
<td align="left" valign="top">3%</td>
<td align="left" valign="top">8%</td>
<td align="left" valign="top">2%</td>
<td align="left" valign="top">4%</td>
<td class="Rrule" align="left" colspan="2" valign="top">2%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="Underline">Cardiovascular</span></td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td class="Rrule" align="left" colspan="2" valign="top"> </td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td align="left" valign="top">5%</td>
<td align="left" valign="top">12%</td>
<td align="left" valign="top">4%</td>
<td align="left" valign="top">10%</td>
<td class="Rrule" align="left" colspan="2" valign="top">5%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span></td>
<td align="left" valign="top">7%</td>
<td align="left" valign="top">11%</td>
<td align="left" valign="top">1%</td>
<td align="left" valign="top">28%</td>
<td class="Rrule" align="left" colspan="2" valign="top">7%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="Underline">Digestive</span></td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td class="Rrule" align="left" colspan="2" valign="top"> </td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="left" valign="top">33%</td>
<td align="left" valign="top">51%</td>
<td align="left" valign="top">9%</td>
<td align="left" valign="top">76%</td>
<td class="Rrule" align="left" colspan="2" valign="top">77%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="left" valign="top">25%</td>
<td align="left" valign="top">45%</td>
<td align="left" valign="top">29%</td>
<td align="left" valign="top">45%</td>
<td class="Rrule" align="left" colspan="2" valign="top">26%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="left" valign="top">23%</td>
<td align="left" valign="top">37%</td>
<td align="left" valign="top">28%</td>
<td align="left" valign="top">53%</td>
<td class="Rrule" align="left" colspan="2" valign="top">49%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></td>
<td align="left" valign="top">8%</td>
<td align="left" valign="top">14%</td>
<td align="left" valign="top">11%</td>
<td align="left" valign="top">18%</td>
<td class="Rrule" align="left" colspan="2" valign="top">9%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="left" valign="top">14%</td>
<td align="left" valign="top">24%</td>
<td align="left" valign="top">16%</td>
<td align="left" valign="top">31%</td>
<td class="Rrule" align="left" colspan="2" valign="top">26%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="Underline">Heme &amp; Lymphatic</span></td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td class="Rrule" align="left" colspan="2" valign="top"> </td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td align="left" valign="top">4%</td>
<td align="left" valign="top">14%</td>
<td align="left" valign="top">9%</td>
<td align="left" valign="top">36%</td>
<td class="Rrule" align="left" colspan="2" valign="top">26%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td align="left" valign="top">3%</td>
<td align="left" valign="top">24%</td>
<td align="left" valign="top">17%</td>
<td align="left" valign="top">52%</td>
<td class="Rrule" align="left" colspan="2" valign="top">34%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="Underline">Metabolic</span></td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td class="Rrule" align="left" colspan="2" valign="top"> </td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></td>
<td align="left" valign="top">10%</td>
<td align="left" valign="top">22%</td>
<td align="left" valign="top">20%</td>
<td align="left" valign="top">20%</td>
<td class="Rrule" align="left" colspan="2" valign="top">17%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td align="left" valign="top">8%</td>
<td align="left" valign="top">10%</td>
<td align="left" valign="top">8%</td>
<td align="left" valign="top">11%</td>
<td class="Rrule" align="left" colspan="2" valign="top">5%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="Underline">Musculoskeletal</span></td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td class="Rrule" align="left" colspan="2" valign="top"> </td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone pain</span></td>
<td align="left" valign="top">7%</td>
<td align="left" valign="top">24%</td>
<td align="left" valign="top">18%</td>
<td align="left" valign="top">7%</td>
<td class="Rrule" align="left" colspan="2" valign="top">7%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="left" valign="top">6%</td>
<td align="left" valign="top">37%</td>
<td align="left" valign="top">21%</td>
<td align="left" valign="top">8%</td>
<td class="Rrule" align="left" colspan="2" valign="top">9%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="Underline">Nervous</span></td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td class="Rrule" align="left" colspan="2" valign="top"> </td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="left" valign="top">14%</td>
<td align="left" valign="top">25%</td>
<td align="left" valign="top">13%</td>
<td align="left" valign="top">29%</td>
<td class="Rrule" align="left" colspan="2" valign="top">15%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="left" valign="top">13%</td>
<td align="left" valign="top">22%</td>
<td align="left" valign="top">24%</td>
<td align="left" valign="top">24%</td>
<td class="Rrule" align="left" colspan="2" valign="top">18%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td align="left" valign="top">9%</td>
<td align="left" valign="top">48%</td>
<td align="left" valign="top">39%</td>
<td align="left" valign="top">17%</td>
<td class="Rrule" align="left" colspan="2" valign="top">11%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td align="left" valign="top">6%</td>
<td align="left" valign="top">12%</td>
<td align="left" valign="top">13%</td>
<td align="left" valign="top">20%</td>
<td class="Rrule" align="left" colspan="2" valign="top">12%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Peripheral neuritis</span></td>
<td align="left" valign="top">2%</td>
<td align="left" valign="top">23%</td>
<td align="left" valign="top">16%</td>
<td align="left" valign="top">2%</td>
<td class="Rrule" align="left" colspan="2" valign="top">2%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">Neuropathy</span></td>
<td align="left" valign="top">1%</td>
<td align="left" valign="top">13%</td>
<td align="left" valign="top">5%</td>
<td align="left" valign="top">4%</td>
<td class="Rrule" align="left" colspan="2" valign="top">4%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="Underline">Respiratory</span></td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td class="Rrule" align="left" colspan="2" valign="top"> </td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough increased</span></td>
<td align="left" valign="top">26%</td>
<td align="left" valign="top">41%</td>
<td align="left" valign="top">22%</td>
<td align="left" valign="top">43%</td>
<td class="Rrule" align="left" colspan="2" valign="top">29%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td align="left" valign="top">22%</td>
<td align="left" valign="top">27%</td>
<td align="left" valign="top">26%</td>
<td align="left" valign="top">42%</td>
<td class="Rrule" align="left" colspan="2" valign="top">25%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td align="left" valign="top">14%</td>
<td align="left" valign="top">22%</td>
<td align="left" valign="top">5%</td>
<td align="left" valign="top">22%</td>
<td class="Rrule" align="left" colspan="2" valign="top">16%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td align="left" valign="top">12%</td>
<td align="left" valign="top">22%</td>
<td align="left" valign="top">14%</td>
<td align="left" valign="top">30%</td>
<td class="Rrule" align="left" colspan="2" valign="top">18%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td align="left" valign="top">9%</td>
<td align="left" valign="top">21%</td>
<td align="left" valign="top">7%</td>
<td align="left" valign="top">13%</td>
<td class="Rrule" align="left" colspan="2" valign="top">6%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="Underline">Skin</span></td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td class="Rrule" align="left" colspan="2" valign="top"> </td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="left" valign="top">18%</td>
<td align="left" valign="top">38%</td>
<td align="left" valign="top">18%</td>
<td align="left" valign="top">27%</td>
<td class="Rrule" align="left" colspan="2" valign="top">17%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   Herpes simplex</td>
<td align="left" valign="top">2%</td>
<td align="left" valign="top">12%</td>
<td align="left" valign="top">3%</td>
<td align="left" valign="top">7%</td>
<td class="Rrule" align="left" colspan="2" valign="top">9%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></td>
<td align="left" valign="top">2%</td>
<td align="left" valign="top">11%</td>
<td align="left" valign="top">3%</td>
<td align="left" valign="top">3%</td>
<td class="Rrule" align="left" colspan="2" valign="top">&lt;  1%</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="Underline">Urogenital</span></td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td align="left" valign="top"> </td>
<td class="Rrule" align="left" colspan="2" valign="top"> </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Botrule" align="left" valign="top">5%</td>
<td class="Botrule" align="left" valign="top">18%</td>
<td class="Botrule" align="left" valign="top">14%</td>
<td class="Botrule" align="left" valign="top">13%</td>
<td class="Botrule Rrule" align="left" colspan="2" valign="top">7%</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Metastatic Gastric Cancer</span></p>
<p>The data below are based on the exposure of 294 patients to Herceptin in combination with a fluoropyrimidine (capecitabine or 5-FU) and cisplatin (Study 7).  In the Herceptin plus chemotherapy arm, the initial dose of Herceptin 8 mg/kg was administered on Day 1 (prior to chemotherapy) followed by 6 mg/kg every  21 days  until disease progression.  Cisplatin was administered at 80 mg/m<span class="Sup">2</span> on Day 1 and the fluoropyrimidine was administered as either capecitabine 1000 mg/m<span class="Sup">2</span> orally twice a day on Days 1-14 or 5-fluorouracil 800 mg/m<span class="Sup">2</span>/day as a continuous intravenous infusion Days 1 through 5.  Chemotherapy was administered for six 21-day cycles.  Median duration of Herceptin treatment was 21 weeks; median number of Herceptin infusions administered was eight.</p>
<a name="table5"></a><table>
<caption><span>Table 5: Study 7:  Per Patient Incidence of Adverse Reactions of All Grades (Incidence  ≥ 5% between Arms) or Grade 3 /4 (Incidence &gt;1% between Arms) and Higher Incidence in Herceptin Arm</span></caption>
<col width="40%">
<col width="15%">
<col width="15%">
<col width="15%">
<col width="15%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule"> </td>
<td class="Botrule" align="center" colspan="2" valign="bottom">Herceptin +FC<br>(N = 294)<br>N (%)</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom">FC<br>(N = 290)<br>N (%)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="bottom">Body System/ Adverse Event</td>
<td class="Botrule" align="center" valign="bottom">All Grades</td>
<td class="Botrule" align="center" valign="bottom">Grades 3/4</td>
<td class="Botrule" align="center" valign="bottom">All Grades</td>
<td class="Botrule Rrule" align="center" valign="bottom">Grades 3/4</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="5" valign="top"><span class="Underline">Investigations</span></td></tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td align="center" valign="top">230 (78)</td>
<td align="center" valign="top">101 (34)</td>
<td align="center" valign="top">212 (73)</td>
<td class="Rrule" align="center" valign="top">83 (29)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></td>
<td align="center" valign="top">83 (28)</td>
<td align="center" valign="top">28 (10)</td>
<td align="center" valign="top">69 (24)</td>
<td class="Rrule" align="center" valign="top">16 (6)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td align="center" valign="top">81 (28)</td>
<td align="center" valign="top">36 (12)</td>
<td align="center" valign="top">61 (21)</td>
<td class="Rrule" align="center" valign="top">30 (10)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td align="center" valign="top">47 (16)</td>
<td align="center" valign="top">14 (5)</td>
<td align="center" valign="top">33 (11)</td>
<td class="Rrule" align="center" valign="top">8 (3)</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="5" valign="top"><span class="Underline">Blood And Lymphatic System Disorders</span></td></tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile Neutropenia</span></td>
<td align="center" valign="top">—</td>
<td align="center" valign="top">15 ( 5)</td>
<td align="center" valign="top">—</td>
<td class="Rrule" align="center" valign="top">8 (3)</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="5" valign="top"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td></tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center" valign="top">109 (37)</td>
<td align="center" valign="top">27 (9)</td>
<td align="center" valign="top">80 (28)</td>
<td class="Rrule" align="center" valign="top">11 (4)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td align="center" valign="top">72 (24)</td>
<td align="center" valign="top">2 (1)</td>
<td align="center" valign="top">43 (15)</td>
<td class="Rrule" align="center" valign="top">6 (2)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span> </td>
<td align="center" valign="top">19 (6)</td>
<td align="center" valign="top">7 (2)</td>
<td align="center" valign="top">10 (3)</td>
<td class="Rrule" align="center" valign="top">1 (≤ 1)</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="5" valign="top"><span class="Underline">Body as a Whole</span></td></tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center" valign="top">102 (35)</td>
<td align="center" valign="top">12 (4)</td>
<td align="center" valign="top">82 (28)</td>
<td class="Rrule" align="center" valign="top">7 ( 2)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td align="center" valign="top">54 (18)</td>
<td align="center" valign="top">3 (1)</td>
<td align="center" valign="top">36 (12)</td>
<td class="Rrule" align="center" valign="top">0 (0)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">Mucosal Inflammation</span></td>
<td align="center" valign="top">37 (13)</td>
<td align="center" valign="top">6 (2)</td>
<td align="center" valign="top">18 (6)</td>
<td class="Rrule" align="center" valign="top">2 (1)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span></td>
<td align="center" valign="top">23 (8)</td>
<td align="center" valign="top">1 (≤ 1)</td>
<td align="center" valign="top">0 (0)</td>
<td class="Rrule" align="center" valign="top">0 (0)</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="5" valign="top"><span class="Underline">Metabolism And Nutrition Disorders</span></td></tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Decrease</span></td>
<td align="center" valign="top">69 (23)</td>
<td align="center" valign="top">6 (2)</td>
<td align="center" valign="top">40 (14)</td>
<td class="Rrule" align="center" valign="top">7 (2)</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="5" valign="top"><span class="Underline"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> And <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></td></tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infections</span></td>
<td align="center" valign="top">56 (19)</td>
<td align="center" valign="top">0 (0)</td>
<td align="center" valign="top">29 (10)</td>
<td class="Rrule" align="center" valign="top">0 (0)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td align="center" valign="top">37 (13)</td>
<td align="center" valign="top">0 (0)</td>
<td align="center" valign="top">17 (6)</td>
<td class="Rrule" align="center" valign="top">0 (0)</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="5" valign="top"><span class="Underline">Renal And Urinary Disorders</span></td></tr>
<tr>
<td class="Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span> and Impairment</td>
<td align="center" valign="top">53 (18)</td>
<td align="center" valign="top">8 (3)</td>
<td align="center" valign="top">42 (15)</td>
<td class="Rrule" align="center" valign="top">5 (2)</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="5" valign="top"><span class="Underline"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td></tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="top">   <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span></td>
<td class="Botrule" align="center" valign="top">28 (10)</td>
<td class="Botrule" align="center" valign="top">0 (0)</td>
<td class="Botrule" align="center" valign="top">14 (5)</td>
<td class="Botrule Rrule" align="center" valign="top">0 (0)</td>
</tr>
</tbody>
</table>
<p> </p>
<p>The following subsections provide additional detail regarding adverse reactions observed in clinical trials of adjuvant breast, metastatic breast cancer, metastatic gastric cancer, or post-marketing experience.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span></span></p>
<p>Serial measurement of cardiac function (LVEF) was obtained in clinical trials in the adjuvant treatment of breast cancer. In Study 3, the median duration of follow-up was 12.6 months (12.4 months in the observation arm; 12.6 months in the 1-year Herceptin arm); and in Studies 1 and 2, 7.9 years in the AC-T arm, 8.3 years in the AC-TH arm. In Studies 1 and 2, 6% of all randomized patients with post-AC LVEF evaluation were not permitted to initiate Herceptin following completion of AC chemotherapy due to cardiac dysfunction (LVEF &lt; LLN or ≥ 16 point decline in LVEF from baseline to end of AC). Following initiation of Herceptin therapy, the incidence of new-onset dose-limiting myocardial dysfunction was higher among patients receiving Herceptin and paclitaxel as compared to those receiving paclitaxel alone in Studies 1 and 2, and in patients receiving one-year Herceptin monotherapy compared to observation in Study 3 (see <a href="#table6">Table 6</a>, <a href="#figure1">Figures 1</a> and <a href="#figure2">2</a>). The per-patient incidence of new-onset cardiac dysfunction, as measured by LVEF, remained similar when compared to the analysis performed at a median follow-up of 2.0 years in the AC-TH arm.  This analysis also showed evidence of reversibility of <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span>, with 64.5% of patients who experienced symptomatic CHF in the AC-TH group being asymptomatic at latest follow-up, and 90.3% having full or partial LVEF recovery.</p>
<a name="table6"></a><table>
<caption><span>Table 6<a name="footnote-reference-13" href="#footnote-13" class="Sup">*</a>: Per-patient Incidence of New Onset Myocardial Dysfunction (by LVEF) Studies 1, 2, 3 and 4</span></caption>
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<thead>
<tr class="First">
<td class="Botrule Lrule" align="left" valign="bottom"></td>
<td class="Botrule" align="center" colspan="3" valign="top">LVEF &lt;50%<br>and Absolute Decrease from Baseline</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Absolute LVEF Decrease</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left" valign="bottom"></td>
<td align="center" valign="bottom">LVEF &lt;50%</td>
<td align="center" valign="bottom">≥10% decrease</td>
<td align="center" valign="bottom">≥16% decrease</td>
<td align="center" valign="bottom">&lt;20% and ≥10%</td>
<td class="Rrule" align="center" valign="bottom">≥20%</td>
</tr>
</thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-13" href="#footnote-reference-13">*</a></dt>
<dd> For Studies 1, 2 and 3, events are counted from the beginning of Herceptin treatment. For Study 4, events are counted from the date of randomization.</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">†</a></dt>
<dd>Studies 1 and 2 regimens: doxorubicin and cyclophosphamide followed by paclitaxel (AC→T) or paclitaxel plus Herceptin (AC→TH).</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">‡</a></dt>
<dd>Median duration of follow-up for studies 1 and 2 combined was 8.3 years in the AC→TH arm.</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">§</a></dt>
<dd>Median follow-up duration of 12.6 months in the one-year Herceptin treatment arm.</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">¶</a></dt>
<dd>Study 4 regimens: doxorubicin and cyclophosphamide followed by docetaxel (AC→T) or docetaxel plus Herceptin (AC→TH); docetaxel and carboplatin plus Herceptin (TCH).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Toprule" align="left" valign="top"><span class="Underline"><span class="Bold">Studies 1 &amp; 2<a name="footnote-reference-14" href="#footnote-14" class="Sup">†</a><span class="Sup">,</span><a name="footnote-reference-15" href="#footnote-15" class="Sup">‡</a></span></span></td>
<td class="Toprule" align="left" valign="top"></td>
<td class="Toprule" align="left" valign="top"></td>
<td class="Toprule" align="left" valign="top"></td>
<td class="Toprule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule" align="center" valign="top">AC→TH<br>(n=1856)</td>
<td align="center" valign="top">23.1%<br>(428)</td>
<td align="center" valign="top">18.5%<br>(344)</td>
<td align="center" valign="top">11.2%<br>(208)</td>
<td align="center" valign="top">37.9%<br>(703)</td>
<td class="Rrule" align="center" valign="top">8.9%<br>(166)</td>
</tr>
<tr>
<td class="Lrule" align="center" valign="top">AC→T<br>(n=1170)</td>
<td align="center" valign="top">11.7%<br>(137)</td>
<td align="center" valign="top">7.0%<br>(82)</td>
<td align="center" valign="top">3.0%<br>(35)</td>
<td align="center" valign="top">22.1%<br>(259)</td>
<td class="Rrule" align="center" valign="top">3.4%<br>(40)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="Underline"><span class="Bold">Study 3<a name="footnote-reference-16" href="#footnote-16" class="Sup">§</a></span></span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule" align="center" valign="top">Herceptin<br>(n=1678)</td>
<td align="center" valign="top">8.6%<br>(144)</td>
<td align="center" valign="top">7.0%<br>(118)</td>
<td align="center" valign="top">3.8%<br>(64)</td>
<td align="center" valign="top">22.4%<br>(376)</td>
<td class="Rrule" align="center" valign="top">3.5%<br>(59)</td>
</tr>
<tr>
<td class="Lrule" align="center" valign="top">Observation<br>(n=1708)</td>
<td align="center" valign="top">2.7%<br>(46)</td>
<td align="center" valign="top">2.0%<br>(35)</td>
<td align="center" valign="top">1.2%<br>(20)</td>
<td align="center" valign="top">11.9%<br>(204)</td>
<td class="Rrule" align="center" valign="top">1.2%<br>(21)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top"><span class="Underline"><span class="Bold">Study 4<a name="footnote-reference-17" href="#footnote-17" class="Sup">¶</a></span></span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule" align="center" valign="top">TCH<br>(n=1056)</td>
<td align="center" valign="top">8.5%<br>(90)</td>
<td align="center" valign="top">5.9%<br>(62)</td>
<td align="center" valign="top">3.3%<br>(35)</td>
<td align="center" valign="top">34.5%<br>(364)</td>
<td class="Rrule" align="center" valign="top">6.3%<br>(67)</td>
</tr>
<tr>
<td class="Lrule" align="center" valign="top">AC→TH<br>(n=1068)</td>
<td align="center" valign="top">17%<br>(182)</td>
<td align="center" valign="top">13.3%<br>(142)</td>
<td align="center" valign="top">9.8%<br>(105)</td>
<td align="center" valign="top">44.3%<br>(473)</td>
<td class="Rrule" align="center" valign="top">13.2%<br>(141)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center" valign="top">AC→T<br>(n=1050)</td>
<td align="center" valign="top">9.5%<br>(100)</td>
<td align="center" valign="top">6.6%<br>(69)</td>
<td align="center" valign="top">3.3%<br>(35)</td>
<td align="center" valign="top">34%<br>(357)</td>
<td class="Rrule" align="center" valign="top">5.5%<br>(58)</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="figure1"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold">Figure 1</span><br> Studies 1 and 2: Cumulative Incidence of Time to First LVEF Decline of ≥ 10 Percentage Points from Baseline and to Below 50% with <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> as a Competing Risk Event </p>
<p><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2&amp;name=herceptin-01.jpg"></p>
<p> Time 0 is initiation of paclitaxel or Herceptin + paclitaxel therapy. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="figure2"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold">Figure 2</span><br>Study 3: Cumulative Incidence of Time to First LVEF Decline of ≥ 10 Percentage Points from Baseline and to Below 50% with <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> as a Competing Risk Event </p>
<p><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2&amp;name=herceptin-02.jpg"></p>
<p>Time 0 is the date of randomization.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="figure3"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Bold">Figure 3</span><br>Study 4: Cumulative Incidence of Time to First LVEF Decline of ≥10 Percentage Points from Baseline and to Below 50% with <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> as a Competing Risk Event </p>
<p><img alt="Figure 3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2&amp;name=herceptin-03.jpg"></p>
<p> Time 0 is the date of randomization. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="id_dc385f56-2e49-4033-8d84-d93c58b740b3"></a><a name="section-6.1.4"></a><p></p>
<p class="First">The incidence of treatment emergent <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> among patients in the metastatic breast cancer trials was classified for severity using the New York Heart Association classification system (I–IV, where IV is the most severe level of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>) (see <a href="#table2">Table 2</a>). In the metastatic breast cancer trials the probability of cardiac dysfunction was highest in patients who received Herceptin concurrently with anthracyclines.</p>
<p>In Study 7, 5.0% of patients in the Herceptin plus chemotherapy arm compared to 1.1% of patients in the chemotherapy alone arm had LVEF value below 50% with a  ≥ 10% absolute decrease in LVEF from pretreatment values.</p>
<p><span class="Italics">Infusion Reactions</span></p>
<p>During the first infusion with Herceptin, the symptoms most commonly reported were <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, occurring in approximately 40% of patients in clinical trials. Symptoms were treated with acetaminophen, diphenhydramine, and meperidine (with or without reduction in the rate of Herceptin infusion); permanent discontinuation of Herceptin for infusional toxicity was required in &lt; 1% of patients. Other signs and/or symptoms may include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (in some cases at tumor sites), <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, elevated blood pressure, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>. Infusional toxicity occurred in 21% and 35% of patients, and was severe in 1.4% and 9% of patients, on second or subsequent Herceptin infusions administered as monotherapy or in combination with chemotherapy, respectively. In the post-marketing setting, severe infusion reactions, including <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> have been reported.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></span></p>
<p>In randomized controlled clinical trials, the overall incidence of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (30% vs. 21% [Study 5]), of selected NCI-CTC Grade 2–5 <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (12.3% vs. 6.7% [Study 1]), and of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> requiring transfusions (0.1% vs. 0 patients [Study 2]) were increased in patients receiving Herceptin and chemotherapy compared with those receiving chemotherapy alone. Following the administration of Herceptin as a single agent (Study 6), the incidence of NCI-CTC Grade 3 <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> was &lt; 1%.  In Study 7 (metastatic gastric cancer) on the Herceptin containing arm as compared to the chemotherapy alone arm the overall incidence of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> was 28% compared 21% and of NCI CTC Grade 3/4 <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> was 12.2% compared to 10.3%.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></span></p>
<p>In randomized controlled clinical trials in the adjuvant setting, the incidence of selected NCI-CTC Grade 4–5 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (1.7% vs. 0.8% [Study 2]) and of selected Grade 2–5 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (6.4% vs. 4.3% [Study 1]) were increased in patients receiving Herceptin and chemotherapy compared with those receiving chemotherapy alone. In a randomized, controlled trial in patients with metastatic breast cancer, the incidences of NCI-CTC Grade 3/4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (32% vs. 22%) and of <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> (23% vs. 17%) were also increased in patients randomized to Herceptin in combination with myelosuppressive chemotherapy as compared to chemotherapy alone.  In Study 7 (metastatic gastric cancer) on the Herceptin containing arm as compared to the chemotherapy alone arm, the incidence of NCI CTC Grade 3/4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> was 36.8% compared to 28.9%; <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> 5.1% compared to 2.8%.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></span></p>
<p>The overall incidences of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (46% vs. 30% [Study 5]), of selected NCI-CTC Grade 2–5 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>/<span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> (24.3% vs. 13.4% [Study 1]) and of selected Grade 3–5 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>/<span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> (2.9% vs. 1.4%) [Study 2]), were higher in patients receiving Herceptin and chemotherapy compared with those receiving chemotherapy alone. The most common site of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in the adjuvant setting involved the upper respiratory tract, skin, and urinary tract.</p>
<p>In Study 4, the overall incidence of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> was higher with the addition of Herceptin to AC-T but not to TCH [44% (AC-TH), 37% (TCH), 38% (AC-T)]. The incidences of NCI-CTC Grade 3-4 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> were similar [25% (AC-TH), 21% (TCH), 23% (AC-T)] across the three arms.</p>
<p>In a randomized, controlled trial in treatment of metastatic breast cancer, the reported incidence of <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> was higher (23% vs. 17%) in patients receiving Herceptin in combination with myelosuppressive chemotherapy as compared to chemotherapy alone.</p>
<p><span class="Italics">Pulmonary Toxicity</span></p>
<p>Adjuvant Breast Cancer </p>
<p>Among women receiving adjuvant therapy for breast cancer, the incidence of selected NCI-CTC Grade 2–5 pulmonary toxicity (14.3% vs. 5.4% [Study 1]) and of selected NCI-CTC Grade 3–5 pulmonary toxicity and spontaneous reported Grade 2 <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (3.4% vs. 0.9% [Study 2]) was higher in patients receiving Herceptin and chemotherapy compared with chemotherapy alone. The most common pulmonary toxicity was <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> (NCI-CTC Grade 2–5: 11.8% vs. 4.6% [Study 1]; NCI-CTC Grade 2–5: 2.4% vs. 0.2% [Study 2]).</p>
<p><span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">Pneumonitis</span>/pulmonary infiltrates occurred in 0.7% of patients receiving Herceptin compared with 0.3% of those receiving chemotherapy alone. Fatal <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span> occurred in 3 patients receiving Herceptin, one as a component of multi-organ system failure, as compared to 1 patient receiving chemotherapy alone.</p>
<p>In Study 3, there were 4 cases of <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">interstitial pneumonitis</span> in the one-year Herceptin treatment arm compared to none in the observation arm at a median follow-up duration of 12.6 months.</p>
<p>Metastatic Breast Cancer</p>
<p>Among women receiving Herceptin for treatment of metastatic breast cancer, the incidence of pulmonary toxicity was also increased. Pulmonary adverse events have been reported in the post-marketing experience as part of the symptom complex of infusion reactions. Pulmonary events include <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, pulmonary infiltrates, <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">pleural effusions</span>, non-cardiogenic <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, and <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">acute respiratory distress syndrome</span>. For a detailed description, see <span class="Italics">Warnings and Precautions (<a href="#i4i_section_ID_warningspulmonarytoxicity">5.4</a>)</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span>/<span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span></span></p>
<p>In 4 randomized, controlled clinical trials, the incidence of thrombotic adverse events was higher in patients receiving Herceptin and chemotherapy compared to chemotherapy alone in three studies (2.6% vs. 1.5% [Study 1], 2.5% and 3.7% vs. 2.2% [Study 4] and 2.1% vs. 0% [Study 5]).</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></span></p>
<p>Among women receiving adjuvant therapy for breast cancer, the incidence of NCI-CTC Grade 2–5 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (6.7% vs. 5.4% [Study 1]) and of NCI-CTC Grade 3–5 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (2.2% vs. 0% [Study 2]), and of Grade 1–4 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (7% vs. 1% [Study 3; one-year Herceptin treatment at 12.6 months median duration of follow-up]) were higher in patients receiving Herceptin as compared to controls. In Study 4, the incidence of Grade 3–4 <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was higher [5.7% AC-TH, 5.5% TCH vs. 3.0% AC-T] and of Grade 1–4 was higher [51% AC-TH, 63% TCH vs. 43% AC-T] among women receiving Herceptin. Of patients receiving Herceptin as a single agent for the treatment of metastatic breast cancer, 25% experienced <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>. An increased incidence of <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> was observed in patients receiving Herceptin in combination with chemotherapy for treatment of metastatic breast cancer.</p>
<p><span class="Italics">Renal Toxicity</span></p>
<p>In Study 7 (metastatic gastric cancer) on the Herceptin-containing arm as compared to the chemotherapy alone arm the incidence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> was 18% compared to 14.5%.  Severe (Grade 3/4) <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> was 2.7% on the Herceptin-containing arm compared to 1.7% on the chemotherapy only arm.  Treatment discontinuation for <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>/failure was 2% on the Herceptin-containing arm and 0.3% on the chemotherapy only arm.</p>
<p>In the postmarketing setting, rare cases of <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> with pathologic evidence of glomerulopathy have been reported. The time to onset ranged from 4 months to approximately 18 months from initiation of Herceptin therapy. Pathologic findings included membranous <span class="product-label-link" type="condition" conceptid="4263367" conceptname="Glomerulonephritis">glomerulonephritis</span>, <span class="product-label-link" type="condition" conceptid="4030513" conceptname="Focal segmental glomerulosclerosis">focal glomerulosclerosis</span>, and fibrillary <span class="product-label-link" type="condition" conceptid="4263367" conceptname="Glomerulonephritis">glomerulonephritis</span>. Complications included volume overload and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_adversereactionsinfusion"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Immunogenicity</h2>
<p class="First">As with all therapeutic proteins, there is a potential for immunogenicity. Among 903 women with metastatic breast cancer, human anti-human antibody (HAHA) to Herceptin was detected in one patient using an enzyme-linked immunosorbent assay (ELISA). This patient did not experience an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. Samples for assessment of HAHA were not collected in studies of adjuvant breast cancer.</p>
<p>The incidence of antibody formation is highly dependent on the sensitivity and the specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Herceptin with the incidence of antibodies to other products may be misleading.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_adversereactionsanemia"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Post-Marketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post approval use of Herceptin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<ul>
<li>Infusion reaction <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_ID_warningsinfusionreactions">5.2</a>)]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">Oligohydramnios</span> or <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> sequence, including <span class="product-label-link" type="condition" conceptid="4213884" conceptname="Congenital hypoplasia of lung">pulmonary hypoplasia</span>, skeletal abnormalities, and neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_ID_warningsembryofetal">5.3</a>)]</span>
</li>
<li>Glomerulopathy <span class="Italics">[see Adverse Reactions (<a href="#i4i_section_ID_adversereactionsclincialtrials">6.1</a>)]</span>
</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_f08abdd5-54cf-42c0-abff-c6af91d6d346"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Patients who receive anthracycline after stopping Herceptin may be at increased risk of cardiac dysfunction because of trastuzumab's long wash out period based on population PK analysis [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].  If possible, physicians should avoid anthracycline-based therapy for up to 7 months after stopping Herceptin.  If anthracyclines are used, the patient's cardiac function should be monitored carefully.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_ID_specificpopulations"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_ID_pregnancy"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Category D <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_ID_warningsembryofetal">5.3</a>)]</span></span></p>
<p>Herceptin can cause fetal harm when administered to a pregnant woman.  In post-marketing reports use of Herceptin during pregnancy resulted in cases of <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> and of <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> sequence, manifesting as <span class="product-label-link" type="condition" conceptid="4213884" conceptname="Congenital hypoplasia of lung">pulmonary hypoplasia</span>, skeletal abnormalities, and neonatal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>These case reports described <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> in pregnant women who received Herceptin either alone or in combination with chemotherapy.  In some case reports, amniotic fluid index increased after Herceptin was stopped.  In one case, Herceptin therapy resumed after the amniotic fluid index improved, and <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> recurred.</p>
<p>Monitor women exposed to Herceptin during pregnancy for <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span>.  If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> occurs, perform fetal testing that is appropriate for gestational age and consistent with community standards of care.  The efficacy of IV hydration in management of <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> due to Herceptin exposure is not known.</p>
<p>Advise women of the potential hazard to the fetus resulting from Herceptin exposure during pregnancy. If Herceptin is administered during pregnancy, or if a patient becomes pregnant while receiving Herceptin or within 7 months following the last dose of Herceptin, immediately report Herceptin exposure to the Genentech Adverse Event Line at 1-888-835-2555. Encourage women who may be exposed to Herceptin during pregnancy or within 7 months of conception, to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720.</p>
<p>No teratogenic effects were observed in offspring from pregnant cynomolgus monkeys administered trastuzumab during the period of organogenesis at doses up to 25 times the recommended weekly human dose of 2 mg/kg.  Trastuzumab administration to cynomolgus monkeys during early gestation (Days 20 to 50) or late gestation (Days 120 to 150) resulted in offspring with trastuzumab plasma levels of 15 to 28% of maternal plasma levels.</p>
<p>In mutant mice lacking HER2, embryos died in early gestation.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_8c61e7a4-c680-4eba-9ea1-c7069e448f96"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether Herceptin is excreted in human milk, but human IgG is excreted in human milk. Published data suggest that breast milk antibodies do not enter the neonatal and infant circulation in substantial amounts.</p>
<p>Trastuzumab was present in the breast milk of lactating cynomolgus monkeys given 12.5 times the recommended weekly human dose of 2 mg/kg of Herceptin. Infant monkeys with detectable serum levels of trastuzumab did not have any adverse effects on growth or development from birth to 3 months of age; however, trastuzumab levels in animal breast milk may not accurately reflect human breast milk levels.</p>
<p>Because many drugs are secreted in human milk and because of the potential for serious adverse reactions in nursing infants from Herceptin, a decision should be made whether to discontinue nursing, or discontinue drug, taking into account the elimination half-life of trastuzumab and the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_9425c732-71f7-46bd-865a-53d48ad2f6a9"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of Herceptin in pediatric patients has not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_6131eea0-e761-4554-9ed4-1ca25875c5a6"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Herceptin has been administered to 386 patients who were 65 years of age or over (253 in the adjuvant treatment and 133 in metastatic breast cancer treatment settings). The risk of cardiac dysfunction was increased in geriatric patients as compared to younger patients in both those receiving treatment for <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span> in Studies 5 and 6, or adjuvant therapy in Studies 1 and 2. Limitations in data collection and differences in study design of the 4 studies of Herceptin in adjuvant treatment of breast cancer preclude a determination of whether the toxicity profile of Herceptin in older patients is different from younger patients. The reported clinical experience is not adequate to determine whether the efficacy improvements (ORR, TTP, OS, DFS) of Herceptin treatment in older patients is different from that observed in patients &lt;65 years of age for <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span> and adjuvant treatment.</p>
<p>In Study 7 (metastatic gastric cancer), of the 294 patients treated with Herceptin 108 (37%) were 65 years of age or older, while 13 (4.4%) were 75 and over.  No overall differences in safety or effectiveness were observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6		Females of Reproductive Potential</h2>
<p class="First">Herceptin can cause embryo-fetal harm when administered during pregnancy.  Advise females of reproductive potential to avoid becoming pregnant while taking Herceptin.  If contraceptive methods are being considered, use effective contraception while receiving Herceptin and for at least 7 months following the last dose of Herceptin <span class="Italics">[see <a href="#i4i_pregnancy_ID_pregnancy">Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_cdd07867-eb47-4d25-9c61-6861721cd26b"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There is no experience with overdosage in human clinical trials. Single doses higher than 8 mg/kg have not been tested.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_bd15cf4e-2f39-4213-80f8-22c1cf382c66"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Herceptin (trastuzumab) is a humanized IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2. Trastuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture containing the antibiotic gentamicin. Gentamicin is not detectable in the final product. </p>
<p>Herceptin is a sterile, white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, preservative-free lyophilized powder for intravenous administration. Each multi-use vial of Herceptin contains 440 mg trastuzumab, 400 mg α,α-trehalose dihydrate, 9.9 mg L-histidine HCl, 6.4 mg L-histidine, and 1.8 mg polysorbate 20, USP. Reconstitution with 20 mL of the appropriate diluent (BWFI or SWFI) yields a solution containing 21 mg/mL trastuzumab at a pH of approximately 6.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_ID_clinicalpharmacology"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e74290fe-accb-4261-a54d-1087b0eb0771"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Herceptin has been shown, in both <span class="Italics">in vitro</span> assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2. </p>
<p>Herceptin is a mediator of antibody-dependent cellular cytotoxicity (ADCC). <span class="Italics">In vitro</span>, Herceptin-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Italics">Cardiac Electrophysiology</span></p>
<p>The effects of trastuzumab on electrocardiographic (ECG) endpoints, including QTc interval duration, were evaluated in patients with HER2 positive <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>.  Trastuzumab had no clinically relevant effect on the QTc interval duration and there was no apparent relationship between serum trastuzumab concentrations and change in QTcF interval duration in patients with HER2 positive <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of trastuzumab was evaluated in a pooled population pharmacokinetic (PK) model analysis of 1,582 subjects with primarily breast cancer and metastatic gastric cancer (MGC) receiving intravenous Herceptin.  Total trastuzumab clearance increases with decreasing concentrations due to parallel linear and non-linear elimination pathways.</p>
<p>Although the average trastuzumab exposure was higher following the first cycle in breast cancer patients receiving the three-weekly schedule compared to the weekly schedule of Herceptin, the average steady-state exposure was essentially the same at both dosages.  The average trastuzumab exposure following the first cycle and at steady state as well as the time to steady state was higher in breast cancer patients compared to MGC patients at the same dosage; however, the reason for this exposure difference is unknown.  Additional predicted trastuzumab exposure and PK parameters following the first Herceptin cycle and at steady state exposure are described in <a href="#table7">Tables 7</a> and <a href="#table8">8</a>, respectively.</p>
<p>Population PK based simulations indicate that following discontinuation of Herceptin, concentrations in at least 95% of breast cancer and MGC patients will decrease to approximately 3% of the population predicted steady-state trough serum concentration (approximately 97% washout) by 7 months <span class="Italics">[see <a href="#i4i_section_ID_warningscardiomyopathy">Warnings and Precautions (5.1)</a></span> and <span class="Italics"><a href="#i4i_pregnancy_ID_pregnancy">Use in Specific Populations (8.1</a>, <a href="#S8.6">8.6)</a></span>].</p>
<a name="table7"></a><table width="75%">
<caption><span>Table 7: Population Predicted Cycle 1 PK Exposures (median with 5<span class="Sup">th</span> - 95<span class="Sup">th</span> Percentiles) in Breast Cancer and MGC Patients</span></caption>
<col align="left" valign="middle" width="15%">
<col align="center" valign="middle" width="17%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="17%">
<col align="center" valign="middle" width="17%">
<col align="center" valign="middle" width="23%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Schedule</th>
<th class="Rrule" align="center">Primary tumor type</th>
<th class="Rrule" align="center">N</th>
<th class="Rrule" align="center">C<span class="Sub">min</span><br>(µg/mL)</th>
<th class="Rrule" align="center">C<span class="Sub">max</span><br>(µg/mL)</th>
<th class="Rrule" align="center">AUC<span class="Sub">0-21days</span><br>(µg.day/mL)</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" rowspan="2">8 mg/kg + 6 mg/kg q3w</td>
<td class="Rrule" align="center">Breast cancer</td>
<td class="Rrule" align="center">1195</td>
<td class="Rrule" align="center">29.4<br>(5.8 -59.5)</td>
<td class="Rrule" align="center">178<br>(117 - 291)</td>
<td class="Rrule" align="center">1373<br>(736 - 2245)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">MGC</td>
<td class="Rrule" align="center">274</td>
<td class="Rrule" align="center">23.1<br>(6.1- 50.3)</td>
<td class="Rrule" align="center">132<br>(84.2 - 225)</td>
<td class="Rrule" align="center">1109<br>(588 - 1938)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">4 mg/kg + 2 mg/kg qw</td>
<td class="Rrule" align="center">Breast cancer</td>
<td class="Rrule" align="center">1195</td>
<td class="Rrule" align="center">37.7<br>(12.3 - 70.9)</td>
<td class="Rrule" align="center">88.3<br>(58 - 144)</td>
<td class="Rrule" align="center">1066<br>(586 - 1754)</td>
</tr>
</tbody>
</table>
<a name="table8"></a><table width="90%">
<caption><span>Table 8: Population Predicted Steady State PK Exposures (median with 5<span class="Sup">th</span> - 95<span class="Sup">th</span> Percentiles) in Breast Cancer and MGC Patients</span></caption>
<col align="left" valign="middle" width="15%">
<col align="left" valign="middle" width="15%">
<col align="left" valign="middle" width="9%">
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="14%">
<col align="center" valign="middle" width="11%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="16%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="center">Schedule</th>
<th class="Rrule" align="left">Primary tumor type</th>
<th class="Rrule" align="left">N</th>
<th class="Rrule" align="center">C<span class="Sub">min,ss</span><a name="footnote-reference-18" href="#footnote-18" class="Sup">*</a><br>(µg/mL)</th>
<th class="Rrule" align="center">C<span class="Sub">max,ss</span><a name="footnote-reference-19" href="#footnote-19" class="Sup">†</a><br>(µg/mL)</th>
<th class="Rrule" align="center">AUC<span class="Sub">ss, 0-21 days</span><br>(µg.day/mL)</th>
<th class="Rrule" align="center">Time to steady-state (week)</th>
<th class="Rrule" align="center">Total CL range at steady-state  (L/day)</th>
</tr></thead>
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-18" href="#footnote-reference-18">*</a></dt>
<dd>Steady-state trough serum concentration of trastuzumab</dd>
<dt><a name="footnote-19" href="#footnote-reference-19">†</a></dt>
<dd>Maximum steady-state serum concentration of trastuzumab</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" rowspan="2">8 mg/kg + 6 mg/kg q3w</td>
<td class="Rrule" align="left">Breast cancer</td>
<td class="Rrule" align="left">1195</td>
<td class="Rrule" align="center">47.4<br>(5 - 115)</td>
<td class="Rrule" align="center">179<br>(107 - 309)</td>
<td class="Rrule" align="center">1794<br>(673 - 3618)</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center" valign="middle">0.173 - 0.283</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">MGC</td>
<td class="Rrule" align="left">274</td>
<td class="Rrule" align="center">32.9<br>(6.1 - 88.9)</td>
<td class="Rrule" align="center">131<br>(72.5 - 251)</td>
<td class="Rrule" align="center">1338<br>(557 - 2875)</td>
<td class="Rrule" align="center">9</td>
<td class="Rrule" align="center" valign="middle">0.189 - 0.337</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">4 mg/kg + 2 mg/kg qw</td>
<td class="Rrule" align="left" valign="top">Breast cancer</td>
<td class="Rrule" align="left" valign="top">1195</td>
<td class="Rrule" align="center">66.1<br>(14.9 – 142)</td>
<td class="Rrule" align="center">109<br>(51.0 - 209)</td>
<td class="Rrule" align="center">1765<br>(647 - 3578)</td>
<td class="Rrule" align="center">12</td>
<td class="Rrule" align="center" valign="middle">0.201 - 0.244</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Italics">Specific Populations: </span> Based on a population pharmacokinetic analysis, no clinically significant differences were observed in the pharmacokinetics of trastuzumab based on age (&lt;65 (n=1294); ≥65 (n=288)), race (Asian (n=264); non-Asian (n=1324)) and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (mild (creatinine clearance [CLcr] 60 to 90 mL/min) (n=636) or moderate (CLcr 30 to 60 mL/min) (n=133)).  The pharmacokinetics of trastuzumab in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, end-stage-<span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> with or without hemodialysis, or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Italics">Drug Interaction Studies:</span></p>
<p>There have been no formal drug interaction studies performed with Herceptin in humans.  Clinically significant interactions between Herceptin and concomitant medications used in clinical trials have not been observed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Italics">Paclitaxel and doxorubicin</span>:  Concentrations of paclitaxel and doxorubicin and their major metabolites (i.e., 6-α hydroxyl-paclitaxel [POH], and doxorubicinol [DOL], respectively) were not altered in the presence of trastuzumab when used as combination therapy in clinical trials.  Trastuzumab concentrations were not altered as part of this combination therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Italics">Docetaxel and carboplatin: </span> When Herceptin was administered in combination with docetaxel or carboplatin, neither the plasma concentrations of docetaxel or carboplatin nor the plasma concentrations of trastuzumab was altered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Italics">Cisplatin and capecitabine</span>:  In a drug interaction substudy conducted in patients in Study 7, the pharmacokinetics of cisplatin, capecitabine and their metabolites were not altered when administered in combination with Herceptin.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_f6cbb9e5-cbc8-467b-9194-c8cda0e899b6"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_c2859646-cbbe-4125-ab3e-2614f001e7d5"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Herceptin has not been tested for carcinogenic potential.</p>
<p>No evidence of mutagenic activity was observed when trastuzumab was tested in the standard Ames bacterial and human peripheral blood lymphocyte mutagenicity assays, at concentrations of up to 5000 mcg/mL. In an <span class="Italics">in vivo</span> micronucleus assay, no evidence of chromosomal damage to mouse bone marrow cells was observed following bolus intravenous doses of up to 118 mg/kg Herceptin.</p>
<p>A fertility study conducted in female cynomolgus monkeys at doses up to 25 times the weekly recommended human dose of 2 mg/kg trastuzumab and has revealed no evidence of impaired fertility, as measured by menstrual cycle duration and female sex hormone levels. Studies to evaluate the effects of trastuzumab on male fertility have not been conducted.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_ID_clinicalstudies"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_study1study2"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Adjuvant Breast Cancer</h2>
<p class="First">The safety and efficacy of Herceptin in women receiving adjuvant chemotherapy for HER2 overexpressing breast cancer, were evaluated in an integrated analysis of two randomized, open-label, clinical trials (Studies 1 and 2) with a total of 4063 women at the protocol-specified final overall survival analysis, a third randomized, open-label, clinical trial (Study 3) with a total of 3386 women at definitive Disease Free Survival analysis for one-year Herceptin treatment versus observation, and a fourth randomized, open-label clinical trial with a total of 3222 patients (Study 4).</p>
<p><span class="Italics">Studies 1 and 2</span></p>
<p>In Studies 1 and 2, breast tumor specimens were required to show HER2 overexpression (3+ by IHC) or gene amplification (by FISH). HER2 testing was verified by a central laboratory prior to randomization (Study 2) or was required to be performed at a reference laboratory (Study 1). Patients with a history of active cardiac disease based on symptoms, abnormal electrocardiographic, radiologic, or left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> findings or <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span> (diastolic &gt; 100 mmHg or systolic &gt; 200 mmHg) were not eligible. </p>
<p>Patients were randomized (1:1) to receive doxorubicin and cyclophosphamide followed by paclitaxel (AC→paclitaxel) alone or paclitaxel plus Herceptin (AC→paclitaxel + Herceptin). In both trials, patients received four 21-day cycles of doxorubicin 60 mg/m<span class="Sup">2</span> and cyclophosphamide 600 mg/m<span class="Sup">2</span>. Paclitaxel was administered either weekly (80 mg/m<span class="Sup">2</span>) or every 3 weeks (175 mg/m<span class="Sup">2</span>) for a total of 12 weeks in Study 1; paclitaxel was administered only by the weekly schedule in Study 2. Herceptin was administered at 4 mg/kg on the day of initiation of paclitaxel and then at a dose of 2 mg/kg weekly for a total of 52 weeks. Herceptin treatment was permanently discontinued in patients who developed <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, or persistent/recurrent LVEF decline <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_ID_dosemodifications">2.2</a>)]</span>. Radiation therapy, if administered, was initiated after the completion of chemotherapy. Patients with ER+ and/or PR+ tumors received hormonal therapy. The primary endpoint of the combined efficacy analysis was Disease-free survival (DFS), defined as the time from randomization to recurrence, occurrence of contralateral breast cancer, other second primary cancer, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The secondary endpoint was overall survival (OS).</p>
<p>A total of 3752 patients were included in the joint efficacy analysis of the primary endpoint of DFS following a median follow-up of 2.0 years in the AC→paclitaxel + Herceptin arm.  The pre-planned final OS analysis from the joint analysis  included 4063 patients and was performed when 707 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> had occurred after a median follow-up of 8.3 years in the AC→paclitaxel + Herceptin arm. The data from both arms in Study 1 and two of the three study arms in Study 2 were pooled for efficacy analyses. The patients included in the primary DFS analysis had a median age of 49 years (range, 22–80 years; 6% &gt; 65 years), 84% were white, 7% black, 4% Hispanic, and 4% Asian/Pacific Islander. Disease characteristics included 90% infiltrating ductal histology, 38% T1, 91% nodal involvement, 27% intermediate and 66% high grade pathology, and 53% ER+ and/or PR+ tumors. Similar demographic and baseline characteristics were reported for the efficacy evaluable population, after 8.3 years of median follow-up in the AC→paclitaxel + Herceptin arm. </p>
<p><span class="Italics">Study 3</span></p>
<p>In Study 3, breast tumor specimens were required to show HER2 overexpression (3+ by IHC) or gene amplification (by FISH) as determined at a central laboratory. Patients with node-negative disease were required to have ≥ T1c primary tumor. Patients with a history of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> or LVEF &lt;55%, uncontrolled <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, angina requiring medication, clinically significant <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">valvular heart disease</span>, evidence of transmural <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> on ECG, poorly controlled <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (systolic &gt; 180 mm Hg or diastolic &gt; 100 mm Hg) were not eligible. </p>
<p>	Study 3 was designed to compare one and two years of three-weekly Herceptin treatment versus observation in patients with HER2 positive EBC following surgery, established chemotherapy and radiotherapy (if applicable).  Patients were randomized (1:1:1) upon completion of definitive surgery, and at least four cycles of chemotherapy to receive no additional treatment, or one year of Herceptin treatment or two years of Herceptin treatment. Patients undergoing a lumpectomy had also completed standard radiotherapy. Patients with ER+ and/or PgR+ disease received systemic adjuvant hormonal therapy at investigator discretion. Herceptin was administered with an initial dose of 8 mg/kg followed by subsequent doses of 6 mg/kg once every three weeks. The main outcome measure was disease-free survival (DFS), defined as in Studies 1 and 2.</p>
<p>A protocol specified interim efficacy analysis comparing one-year Herceptin treatment to observation was performed at a median follow-up duration of 12.6 months in the Herceptin arm and formed the basis for the definitive DFS results from this study.  Among the 3386 patients randomized to the observation (n =1693) and Herceptin one-year (n= 1693) treatment arms, the median age was 49 years (range 21–80), 83% were Caucasian, and 13% were Asian. Disease characteristics: 94% infiltrating ductal carcinoma, 50% ER+ and/or PgR+, 57% node positive, 32% node negative, and in 11% of patients, nodal status was not assessable due to prior neo-adjuvant chemotherapy. Ninety-six percent (1055/1098) of patients with node-negative disease had high risk features: among the 1098 patients with node-negative disease, 49% (543) were ER− and PgR−, and 47% (512) were ER and/or PgR + and had at least one of the following high risk features: pathological tumor size greater than 2 cm, Grade 2–3, or age &lt; 35 years. Prior to randomization, 94% of patients had received anthracycline-based chemotherapy regimens. </p>
<p>After the definitive DFS results comparing observation to one-year Herceptin treatment were disclosed, a prospectively planned analysis that included comparison of one year versus two years of Herceptin treatment at a median follow-up duration of 8 years was performed. Based on this analysis, extending Herceptin treatment for a duration of two years did not show additional benefit over treatment for one year [Hazard Ratios of two-years Herceptin versus one-year Herceptin treatment in the intent to treat (ITT) population for Disease Free Survival (DFS) = 0.99 (95% CI: 0.87, 1.13), p-value = 0.90 and Overall Survival (OS) = 0.98 (0.83, 1.15); p-value= 0.78].  </p>
<p><span class="Italics">Study 4</span></p>
<p>In Study 4, breast tumor specimens were required to show HER2 gene amplification (FISH+ only) as determined at a central laboratory. Patients were required to have either node-positive disease, or node-negative disease with at least one of the following high-risk features: ER/PR-negative, tumor size &gt; 2 cm, age &lt; 35 years, or histologic and/or nuclear Grade 2 or 3. Patients with a history of CHF, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>, angina requiring medication, clinically significant <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">valvular heart disease</span>, poorly controlled <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (diastolic &gt; 100 mmHg), any T4 or N2 or known N3 or M1 breast cancer were not eligible.</p>
<p>Patients were randomized (1:1:1) to receive doxorubicin and cyclophosphamide followed by docetaxel (AC-T), doxorubicin and cyclophosphamide followed by docetaxel plus Herceptin (AC-TH), or docetaxel and carboplatin plus Herceptin (TCH). In both the AC-T and AC-TH arms, doxorubicin 60 mg/m<span class="Sup">2</span> and cyclophosphamide 600 mg/m<span class="Sup">2</span> were administered every 3 weeks for four cycles; docetaxel 100 mg/m <span class="Sup">2</span> was administered every 3 weeks for four cycles. In the TCH arm, docetaxel 75 mg/m<span class="Sup">2</span> and carboplatin (at a target AUC of 6 mg/mL/min as a 30- to 60-minute infusion) were administered every 3 weeks for six cycles. Herceptin was administered weekly (initial dose of 4 mg/kg followed by weekly dose of 2 mg/kg) concurrently with either T or TC, and then every 3 weeks (6 mg/kg) as monotherapy for a total of 52 weeks. Radiation therapy, if administered, was initiated after completion of chemotherapy. Patients with ER+ and/or PR+ tumors received hormonal therapy. Disease-free survival (DFS) was the main outcome measure.</p>
<p>Among the 3222 patients randomized, the median age was 49 (range 22 to 74 years; 6% ≥ 65 years). Disease characteristics included 54% ER+ and/or PR+ and 71% node positive. Prior to randomization, all patients underwent primary surgery for breast cancer.</p>
<p>The results for DFS for the integrated analysis of Studies 1 and 2, Study 3, and Study 4 and OS results for the integrated analysis of Studies 1 and 2, and Study 3 are presented in <a href="#table9">Table 9</a>. For Studies 1 and 2, the duration of DFS following a median follow-up of 2.0 years in the AC→TH arm, is presented in<a href="#figure4"> Figure 4</a>, and the duration of OS after a median follow-up of 8.3 years in the AC→TH arm is presented in<a href="#fig5"> Figure 5</a>. The duration of DFS for Study 4 is presented in<a href="#figure6"> Figure 6</a>. Across all four studies, at the time of definitive DFS analysis, there were insufficient numbers of patients within each of the following subgroups to determine if the treatment effect was different from that of the overall patient population: patients with low tumor grade, patients within specific ethnic/racial subgroups (Black, Hispanic, Asian/Pacific Islander patients), and patients &gt; 65 years of age. For Studies 1 and 2, the OS hazard ratio was 0.64 (95% CI: 0.55, 0.74).  At 8.3 years of median follow up [AC→TH], the survival rate was estimated to be 86.9% in the AC→TH arm and 79.4% in the AC→T arm. The final OS analysis results from Studies 1 and 2 indicate that OS benefit by age, hormone receptor status, number of positive lymph nodes, tumor size and grade, and surgery/radiation therapy, was consistent with the treatment effect in the overall population. In patients ≤ 50 years of age (n=2197), the OS hazard ratio was 0.65 (95% CI: 0.52, 0.81) and in patients &gt; 50 years of age (n=1866), the OS hazard ratio was 0.63 (95% CI: 0.51, 0.78). In the subgroup of patients with hormone receptor-positive disease (ER-positive and/or PR-positive) (n=2223), the hazard ratio for OS was 0.63 (95% CI: 0.51, 0.78). In the subgroup of patients with hormone receptor-negative disease (ER-negative and PR-negative) (n=1830), the hazard ratio for OS was 0.64 (95% CI: 0.52, 0.80). In the subgroup of patients with tumor size ≤2 cm (n=1604), the hazard ratio for OS was 0.52 (95% CI: 0.39, 0.71). In the subgroup of patients with tumor size &gt;2 cm (n=2448), the hazard ratio for OS was 0.67 (95% CI: 0.56, 0.80).</p>
<a name="table9"></a><table width="75%">
<caption><span>Table 9: Efficacy Results from Adjuvant Treatment of Breast Cancer (Studies 1 + 2, Study 3, and Study 4)</span></caption>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th align="center">DFS events</th>
<th align="center">DFS Hazard ratio<br>(95% CI)<br>p value</th>
<th align="center"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span><br>(OS events)</th>
<th class="Rrule" align="center">OS Hazard ratio<br>p value</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="5">CI = confidence interval.</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-20" href="#footnote-reference-20">*</a></dt>
<dd>Studies 1 and 2 regimens: doxorubicin and cyclophosphamide followed by paclitaxel (AC→T) or paclitaxel plus Herceptin (AC→TH).</dd>
<dt><a name="footnote-21" href="#footnote-reference-21">†</a></dt>
<dd>Efficacy evaluable population, for the primary DFS analysis, following a median follow-up of 2.0 years in the AC→TH arm.</dd>
<dt><a name="footnote-22" href="#footnote-reference-22">‡</a></dt>
<dd>Efficacy evaluable population, for the final OS analysis, following 707 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> (8.3 years of median follow-up in the AC→TH arm).</dd>
<dt><a name="footnote-23" href="#footnote-reference-23">§</a></dt>
<dd>Hazard ratio estimated by Cox regression stratified by clinical trial, intended paclitaxel schedule, number of positive nodes, and hormone receptor status.</dd>
<dt><a name="footnote-24" href="#footnote-reference-24">¶</a></dt>
<dd>stratified log-rank test.</dd>
<dt><a name="footnote-25" href="#footnote-reference-25">#</a></dt>
<dd>At definitive DFS analysis with median duration of follow-up of 12.6 months in the one-year Herceptin treatment arm.</dd>
<dt><a name="footnote-26" href="#footnote-reference-26">Þ</a></dt>
<dd>log-rank test.</dd>
<dt><a name="footnote-27" href="#footnote-reference-27">ß</a></dt>
<dd>NS= non-significant.</dd>
<dt><a name="footnote-28" href="#footnote-reference-28">à</a></dt>
<dd>Study 4 regimens: doxorubicin and cyclophosphamide followed by docetaxel (AC→T) or docetaxel plus Herceptin (AC→TH); docetaxel and carboplatin plus Herceptin (TCH).</dd>
<dt><a name="footnote-29" href="#footnote-reference-29">è</a></dt>
<dd>A two-sided alpha level of 0.025 for each comparison.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First"><td class="Lrule Rrule" align="left" colspan="5">Studies 1 + 2<a name="footnote-reference-20" href="#footnote-20" class="Sup">*</a>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">AC→TH<br>(n =1872)<a name="footnote-reference-21" href="#footnote-21" class="Sup">†</a><br>(n = 2031)<a name="footnote-reference-22" href="#footnote-22" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">133<a href="#footnote-21" class="Sup">†</a>
</td>
<td class="Rrule" align="center">0.48<a href="#footnote-21" class="Sup">†</a><span class="Sup">,</span><a name="footnote-reference-23" href="#footnote-23" class="Sup">§</a><br>(0.39, 0.59)<br>p&lt; 0.0001<a name="footnote-reference-24" href="#footnote-24" class="Sup">¶</a>
</td>
<td class="Rrule" align="center">289<a href="#footnote-22" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">0.64<a href="#footnote-22" class="Sup">‡</a><span class="Sup">,</span><a href="#footnote-23" class="Sup">§</a><br>(0.55, 0.74)<br>p&lt; 0.0001<a href="#footnote-24" class="Sup">¶</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">AC→T<br>(n = 1880)<a href="#footnote-21" class="Sup">†</a><br>(n = 2032)<a href="#footnote-22" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">261<a href="#footnote-21" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">418<a href="#footnote-22" class="Sup">‡</a>
</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5">Study 3<a name="footnote-reference-25" href="#footnote-25" class="Sup">#</a>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Chemo→<br>Herceptin<br>(n =1693 )</td>
<td class="Rrule" align="center">127</td>
<td class="Rrule" align="center">0.54<br>(0.44, 0.67)<br>p&lt; 0.0001<a name="footnote-reference-26" href="#footnote-26" class="Sup">Þ</a>
</td>
<td class="Rrule" align="center">31</td>
<td class="Rrule" align="center">0.75<br>p=NS<a name="footnote-reference-27" href="#footnote-27" class="Sup">ß</a>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Chemo→<br>  Observation<br>  (n = 1693)</td>
<td class="Rrule" align="center">219</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">40</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule"><td class="Lrule Rrule" align="left" colspan="5">Study 4<a name="footnote-reference-28" href="#footnote-28" class="Sup">à</a>
</td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">TCH<br>(n=1075)</td>
<td class="Rrule" align="center">134</td>
<td class="Rrule" align="center">0.67<br>(0.54 – 0.84)<br>p=0.0006<a href="#footnote-24" class="Sup">¶</a><span class="Sup">,</span><a name="footnote-reference-29" href="#footnote-29" class="Sup">è</a>
</td>
<td class="Rrule" align="center">56</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">AC→TH<br>(n=1074)</td>
<td class="Rrule" align="center">121</td>
<td class="Rrule" align="center">0.60<br>(0.48 – 0.76)<br>p&lt; 0.0001<a href="#footnote-24" class="Sup">¶</a><span class="Sup">,</span><a href="#footnote-28" class="Sup">à</a>
</td>
<td class="Rrule" align="center">49</td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">AC→T<br>(n=1073)</td>
<td class="Rrule" align="center">180</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">80</td>
<td class="Rrule" align="center"></td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="figure4"></a><a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Bold">Figure 4</span><br>Duration of Disease-Free Survival in Patients with Adjuvant Treatment of Breast Cancer (Studies 1 and 2) </p>
<p><img alt="Figure 4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2&amp;name=herceptin-04.jpg"></p>
<a name="fig5"></a><table class="Noautorules" width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr><td align="center">
<span class="Bold">Figure 5</span><br>Duration of Overall Survival in Patients with<br>Adjuvant Treatment of Breast Cancer (Studies 1 and 2)</td></tr>
<tr><td align="center"><img alt="Figure 5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2&amp;name=herceptin-05.jpg"></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="figure6"></a><a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Bold">Figure 6</span><br>Duration of Disease-Free Survival in Patients with Adjuvant Treatment of Breast Cancer (Study 4)</p>
<p><img alt="Figure 6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2&amp;name=herceptin-06.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="id_1f6bfe93-2aec-4aa2-9007-2f34f9598ebb"></a><a name="section-13.1.3"></a><p></p>
<p class="First">Exploratory analyses of DFS as a function of HER2 overexpression or gene amplification were conducted for patients in Studies 2 and 3, where central laboratory testing data were available. The results are shown in <a href="#table10">Table 10</a>. The number of events in Study 2 was small with the exception of the IHC 3+/FISH+ subgroup, which constituted 81% of those with data. Definitive conclusions cannot be drawn regarding efficacy within other subgroups due to the small number of events. The number of events in Study 3 was adequate to demonstrate significant effects on DFS in the IHC 3+/FISH unknown and the FISH +/IHC unknown subgroups. </p>
<a name="table10"></a><table>
<caption><span>Table 10: Treatment Outcomes in Studies 2 and 3 as a Function of HER2 Overexpression or Amplification</span></caption>
<col align="left" width="20%">
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="20%">
<thead>
<tr class="First">
<td class="Lrule Toprule" align="left" valign="top"> </td>
<td class="Botrule" align="center" colspan="2" valign="top">Study 2</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">Study 3<a name="footnote-reference-30" href="#footnote-30" class="Sup">*</a>
</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left" valign="top">HER2 Assay Result<a name="footnote-reference-31" href="#footnote-31" class="Sup">†</a>
</td>
<td align="center" valign="top">Number of Patients</td>
<td align="center" valign="top">Hazard Ratio DFS (95% CI)</td>
<td align="center" valign="top">Number of Patients</td>
<td class="Rrule" align="center" valign="top">Hazard Ratio DFS (95% CI)</td>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-30" href="#footnote-reference-30">*</a></dt>
<dd>Median follow-up duration of 12.6 months in the one-year Herceptin treatment arm.</dd>
<dt><a name="footnote-31" href="#footnote-reference-31">†</a></dt>
<dd>IHC by HercepTest, FISH by PathVysion (HER2/CEP17 ratio ≥ 2.0) as performed at a central laboratory.</dd>
<dt><a name="footnote-32" href="#footnote-reference-32">‡</a></dt>
<dd>All cases in this category in Study 3 were IHC 2+.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Lrule Rrule" align="left" colspan="5" valign="top">IHC 3+</td></tr>
<tr>
<td class="Lrule" align="left" valign="top">    FISH (+)</td>
<td align="center" valign="top">1170</td>
<td align="center" valign="top">0.42<br> (0.27, 0.64)</td>
<td align="center" valign="top">91</td>
<td class="Rrule" align="center" valign="top">0.56<br> (0.13, 2.50)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">    FISH (−)</td>
<td align="center" valign="top">51</td>
<td align="center" valign="top">0.71<br> (0.04, 11.79)</td>
<td align="center" valign="top">8</td>
<td class="Rrule" align="center" valign="top">—</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">    FISH Unknown</td>
<td class="Botrule" align="center" valign="top">51</td>
<td class="Botrule" align="center" valign="top">0.69<br>(0.09, 5.14)</td>
<td class="Botrule" align="center" valign="top">2258</td>
<td class="Botrule Rrule" align="center" valign="top">0.53<br> (0.41, 0.69)</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" valign="top">IHC &lt; 3+ / <br>FISH (+)</td>
<td class="Botrule" align="center" valign="top">174</td>
<td class="Botrule" align="center" valign="top">1.01<br>(0.18, 5.65)</td>
<td class="Botrule" align="center" valign="top">299<a name="footnote-reference-32" href="#footnote-32" class="Sup">‡</a>
</td>
<td class="Botrule Rrule" align="center" valign="top">0.53<br> (0.20, 1.42)</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left" valign="top">IHC unknown / FISH (+)</td>
<td align="center" valign="top">—</td>
<td align="center" valign="top">—</td>
<td align="center" valign="top">724</td>
<td class="Rrule" align="center" valign="top">0.59<br> (0.38, 0.93)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_study3"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Metastatic Breast Cancer</h2>
<p class="First">The safety and efficacy of Herceptin in treatment of women with metastatic breast cancer were studied in a randomized, controlled clinical trial in combination with chemotherapy (Study 5, n=469 patients) and an open-label single agent clinical trial (Study 6, n=222 patients). Both trials studied patients with metastatic breast cancer whose tumors overexpress the HER2 protein. Patients were eligible if they had 2 or 3 levels of overexpression (based on a 0 to 3 scale) by immunohistochemical assessment of tumor tissue performed by a central testing lab.</p>
<p><span class="Italics">Previously Untreated Metastatic Breast Cancer (Study 5)</span></p>
<p>Study 5 was a multicenter, randomized, open-label clinical trial conducted in 469 women with metastatic breast cancer who had not been previously treated with chemotherapy for <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>. Tumor specimens were tested by IHC (Clinical Trial Assay, CTA) and scored as 0, 1+, 2+, or 3+, with 3+ indicating the strongest positivity. Only patients with 2+ or 3+ positive tumors were eligible (about 33% of those screened). Patients were randomized to receive chemotherapy alone or in combination with Herceptin given intravenously as a 4 mg/kg loading dose followed by weekly doses of Herceptin at 2 mg/kg. For those who had received prior anthracycline therapy in the adjuvant setting, chemotherapy consisted of paclitaxel (175 mg/m<span class="Sup">2</span> over 3 hours every 21 days for at least six cycles); for all other patients, chemotherapy consisted of anthracycline plus cyclophosphamide (AC: doxorubicin 60 mg/m<span class="Sup">2</span> or epirubicin 75 mg/m<span class="Sup">2</span> plus 600 mg/m<span class="Sup">2</span> cyclophosphamide every 21 days for six cycles). Sixty-five percent of patients randomized to receive chemotherapy alone in this study received Herceptin at the time of disease progression as part of a separate extension study. </p>
<p>Based upon the determination by an independent response evaluation committee the patients randomized to Herceptin and chemotherapy experienced a significantly longer median time to disease progression, a higher overall response rate (ORR), and a longer median duration of response, as compared with patients randomized to chemotherapy alone. Patients randomized to Herceptin and chemotherapy also had a longer median survival (see <a href="#table11">Table 11</a>). These treatment effects were observed both in patients who received Herceptin plus paclitaxel and in those who received Herceptin plus AC; however the magnitude of the effects was greater in the paclitaxel subgroup. </p>
<a name="table11"></a><table>
<caption><span>Table 11: Study 5:  Efficacy Results in First-Line Treatment for Metastatic Breast Cancer</span></caption>
<col align="left" width="30%">
<col align="center" width="12%">
<col align="center" width="12%">
<col align="center" width="12%">
<col align="center" width="12%">
<col align="center" width="12%">
<col align="center" width="10%">
<thead>
<tr class="First">
<td class="Lrule Toprule" align="left" valign="top"> </td>
<td class="Botrule Toprule" align="center" colspan="2" valign="top">Combined Results</td>
<td class="Botrule Toprule" align="center" colspan="2" valign="top">Paclitaxel Subgroup</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="top">AC Subgroup</td>
</tr>
<tr class="Last">
<td class="Lrule" align="center" valign="bottom"> </td>
<td align="center" valign="bottom">Herceptin + All Chemotherapy<br>(n = 235)</td>
<td align="center" valign="bottom">All Chemotherapy<br>(n = 234)</td>
<td align="center" valign="bottom">Herceptin + Paclitaxel<br>(n = 92)</td>
<td align="center" valign="bottom">Paclitaxel<br>(n = 96)</td>
<td align="center" valign="bottom">Herceptin + AC<a name="footnote-reference-33" href="#footnote-33" class="Sup">*</a><br>(n = 143)</td>
<td class="Rrule" align="center" valign="bottom">AC<br> (n = 138)</td>
</tr>
</thead>
<tfoot><tr><td colspan="7" align="left"><dl class="Footnote">
<dt><a name="footnote-33" href="#footnote-reference-33">*</a></dt>
<dd>AC = Anthracycline (doxorubicin or epirubicin) and cyclophosphamide.</dd>
<dt><a name="footnote-34" href="#footnote-reference-34">†</a></dt>
<dd>Assessed by an independent Response Evaluation Committee.</dd>
<dt><a name="footnote-35" href="#footnote-reference-35">‡</a></dt>
<dd>Kaplan-Meier Estimate.</dd>
<dt><a name="footnote-36" href="#footnote-reference-36">§</a></dt>
<dd>log-rank test.</dd>
<dt><a name="footnote-37" href="#footnote-reference-37">¶</a></dt>
<dd>Χ<span class="Sup">2</span>-test.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Lrule Rrule" align="left" colspan="7" valign="top"><span class="Underline"><span class="Bold">Primary Endpoint</span></span></td></tr>
<tr>
<td class="Lrule" align="left" valign="top">
<span class="Underline">Median TTP (mos)</span><a name="footnote-reference-34" href="#footnote-34" class="Sup">†</a><span class="Sup">, </span><a name="footnote-reference-35" href="#footnote-35" class="Sup">‡</a>
</td>
<td align="center" valign="top">7.2</td>
<td align="center" valign="top">4.5</td>
<td align="center" valign="top">6.7</td>
<td align="center" valign="top">2.5</td>
<td align="center" valign="top">7.6</td>
<td class="Rrule" align="center" valign="top">5.7</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">    95% CI</td>
<td align="center" valign="top">7, 8</td>
<td align="center" valign="top">4, 5</td>
<td align="center" valign="top">5, 10</td>
<td align="center" valign="top">2, 4</td>
<td align="center" valign="top">7, 9</td>
<td class="Rrule" align="center" valign="top">5, 7</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">    p-value<a name="footnote-reference-36" href="#footnote-36" class="Sup">§</a>
</td>
<td align="center" colspan="2" valign="top">&lt; 0.0001</td>
<td align="center" colspan="2" valign="top">&lt; 0.0001</td>
<td class="Rrule" align="center" colspan="2" valign="top">0.002</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="7" valign="top"><span class="Underline"><span class="Bold">Secondary Endpoints</span></span></td></tr>
<tr>
<td class="Lrule" align="left" valign="top">
<span class="Underline">Overall Response Rate</span><a href="#footnote-34" class="Sup">†</a>
</td>
<td align="center" valign="top">45</td>
<td align="center" valign="top">29</td>
<td align="center" valign="top">38</td>
<td align="center" valign="top">15</td>
<td align="center" valign="top">50</td>
<td class="Rrule" align="center" valign="top">38</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">    95% CI</td>
<td align="center" valign="top">39, 51</td>
<td align="center" valign="top">23, 35</td>
<td align="center" valign="top">28, 48</td>
<td align="center" valign="top">8, 22</td>
<td align="center" valign="top">42, 58</td>
<td class="Rrule" align="center" valign="top">30, 46</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">    p-value<a name="footnote-reference-37" href="#footnote-37" class="Sup">¶</a>
</td>
<td align="center" colspan="2" valign="top"> &lt; 0.001</td>
<td align="center" colspan="2" valign="top"> &lt; 0.001</td>
<td class="Rrule" align="center" colspan="2" valign="top">0.10</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">
<span class="Underline">Median Resp Duration (mos)</span><a href="#footnote-34" class="Sup">†</a><span class="Sup">,</span><a href="#footnote-35" class="Sup">‡</a>
</td>
<td align="center" valign="top">8.3</td>
<td align="center" valign="top">5.8</td>
<td align="center" valign="top">8.3</td>
<td align="center" valign="top">4.3</td>
<td align="center" valign="top">8.4</td>
<td class="Rrule" align="center" valign="top">6.4</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">    25%, 75% Quartile</td>
<td align="center" valign="top">6, 15</td>
<td align="center" valign="top">4, 8</td>
<td align="center" valign="top">5 ,11</td>
<td align="center" valign="top">4, 7</td>
<td align="center" valign="top">6, 15</td>
<td class="Rrule" align="center" valign="top">4, 8</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">
<span class="Underline">Med Survival (mos)</span><a href="#footnote-35" class="Sup">‡</a>
</td>
<td align="center" valign="top">25.1</td>
<td align="center" valign="top">20.3</td>
<td align="center" valign="top">22.1</td>
<td align="center" valign="top">18.4</td>
<td align="center" valign="top">26.8</td>
<td class="Rrule" align="center" valign="top">21.4</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">    95% CI</td>
<td align="center" valign="top">22, 30</td>
<td align="center" valign="top">17, 24</td>
<td align="center" valign="top">17, 29</td>
<td align="center" valign="top">13, 24</td>
<td align="center" valign="top">23, 33</td>
<td class="Rrule" align="center" valign="top">18, 27</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left" valign="top">    p-value<a href="#footnote-36" class="Sup">§</a>
</td>
<td align="center" colspan="2" valign="top">0.05</td>
<td align="center" colspan="2" valign="top">0.17</td>
<td class="Rrule" align="center" colspan="2" valign="top">0.16</td>
</tr>
</tbody>
</table>
<p>Data from Study 5 suggest that the beneficial treatment effects were largely limited to patients with the highest level of HER2 protein overexpression (3+) (see <a href="#table12">Table 12</a>). </p>
<a name="table12"></a><table>
<caption><span>Table 12: Treatment Effects in Study 5 as a Function of HER2 Overexpression or Amplification</span></caption>
<col align="left" width="15%">
<col align="center" width="15%">
<col align="center" width="22.5%">
<col align="center" width="22.5%">
<thead><tr class="First Last">
<td class="Botrule Lrule" align="center" valign="bottom">HER2 Assay Result</td>
<td class="Botrule" align="center" valign="bottom">Number of Patients<br>(N)</td>
<td class="Botrule" align="center" valign="bottom">Relative Risk<a name="footnote-reference-38" href="#footnote-38" class="Sup">*</a> for Time to Disease Progression<br>(95% CI)</td>
<td class="Botrule Rrule" align="center" valign="bottom">Relative Risk <a href="#footnote-38" class="Sup">*</a> for Mortality<br>(95% CI)</td>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-38" href="#footnote-reference-38">*</a></dt>
<dd>The relative risk represents the risk of progression or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in the Herceptin plus chemotherapy arm versus the chemotherapy arm.</dd>
<dt><a name="footnote-39" href="#footnote-reference-39">†</a></dt>
<dd>FISH testing results were available for 451 of the 469 patients enrolled on study.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Toprule" align="left" valign="top">CTA 2+ or 3+</td>
<td class="Toprule" align="center" valign="bottom">469</td>
<td class="Toprule" align="center" valign="bottom">0.49 (0.40, 0.61)</td>
<td class="Rrule" align="center" valign="bottom">0.80 (0.64, 1.00)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">    FISH (+) <a name="footnote-reference-39" href="#footnote-39" class="Sup">†</a>
</td>
<td align="center" valign="bottom">325</td>
<td align="center" valign="bottom">0.44 (0.34, 0.57)</td>
<td class="Rrule" align="center" valign="bottom">0.70 (0.53, 0.91)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">    FISH (−)<a href="#footnote-39" class="Sup">†</a>
</td>
<td align="center" valign="bottom">126</td>
<td align="center" valign="bottom">0.62 (0.42, 0.94)</td>
<td class="Rrule" align="center" valign="bottom">1.06 (0.70, 1.63)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">CTA 2+</td>
<td align="center" valign="bottom">120</td>
<td align="center" valign="bottom">0.76 (0.50, 1.15)</td>
<td class="Rrule" align="center" valign="bottom">1.26 (0.82, 1.94)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">    FISH (+)   </td>
<td align="center" valign="bottom">32</td>
<td align="center" valign="bottom">0.54 (0.21, 1.35)</td>
<td class="Rrule" align="center" valign="bottom">1.31 (0.53, 3.27)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">    FISH (–)</td>
<td align="center" valign="bottom">83</td>
<td align="center" valign="bottom">0.77 (0.48, 1.25)</td>
<td class="Rrule" align="center" valign="bottom">1.11 (0.68, 1.82)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">CTA 3+</td>
<td align="center" valign="bottom">349</td>
<td align="center" valign="bottom">0.42 (0.33, 0.54)</td>
<td class="Rrule" align="center" valign="bottom">0.70 (0.51, 0.90)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="top">    FISH (+)</td>
<td align="center" valign="bottom">293</td>
<td align="center" valign="bottom">0.42 (0.32, 0.55)</td>
<td class="Rrule" align="center" valign="bottom">0.67 (0.51, 0.89)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="top">    FISH (–)</td>
<td class="Botrule" align="center" valign="bottom">43</td>
<td class="Botrule" align="center" valign="bottom">0.43 (0.20, 0.94)</td>
<td class="Botrule Rrule" align="center" valign="bottom">0.88 (0.39, 1.98)</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Previously Treated Metastatic Breast Cancer (Study 6)</span></p>
<p>Herceptin was studied as a single agent in a multicenter, open-label, single-arm clinical trial (Study 6) in patients with HER2 overexpressing metastatic breast cancer who had relapsed following one or two prior chemotherapy regimens for <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>. Of 222 patients enrolled, 66% had received prior adjuvant chemotherapy, 68% had received two prior chemotherapy regimens for <span class="product-label-link" type="condition" conceptid="4116496" conceptname="Disseminated adenocarcinoma">metastatic disease</span>, and 25% had received prior myeloablative treatment with hematopoietic rescue. Patients were treated with a loading dose of 4 mg/kg IV followed by weekly doses of Herceptin at 2 mg/kg IV. </p>
<p>The ORR (complete response+partial response), as determined by an independent Response Evaluation Committee, was 14%, with a 2% complete response rate and a 12% partial response rate. Complete responses were observed only in patients with disease limited to skin and lymph nodes. The overall response rate in patients whose tumors tested as CTA 3+ was 18% while in those that tested as CTA 2+, it was 6%. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7f6714a1-af13-482e-a25e-1dd7cfcd8bd0"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Metastatic Gastric Cancer</h2>
<p class="First">The safety and efficacy of Herceptin in combination with cisplatin and a fluoropyrimidine (capecitabine or 5-fluorouracil) were studied in patients previously untreated for metastatic gastric or gastroesophageal junction adenocarcinoma (Study 7).  In this open-label, multi-center trial, 594 patients were randomized 1:1 to Herceptin in combination with cisplatin and a fluoropyrimidine (FC+H) or chemotherapy alone (FC).  Randomization was stratified by extent of disease (metastatic vs. locally advanced), primary site (gastric vs. gastroesophageal junction), tumor measurability (yes vs. no), ECOG performance status (0,1 vs. 2), and fluoropyrimidine (capecitabine vs. 5-fluorouracil).  All patients were either HER2 gene amplified (FISH+) or HER2 overexpressing (IHC 3+).  Patients were also required to have adequate cardiac function (e.g., LVEF &gt; 50%).</p>
<p>On the Herceptin-containing arm, Herceptin was administered as an IV infusion at an initial dose of 8 mg/kg followed by 6 mg/kg every 3 weeks until disease progression.  On both study arms cisplatin was administered at a dose of 80 mg/m<span class="Sup">2</span> Day 1 every 3 weeks for 6 cycles as a 2 hour IV infusion.  On both study arms capecitabine was administered at 1000 mg/m<span class="Sup">2</span> dose orally twice daily (total daily dose 2000 mg/m<span class="Sup">2</span>) for 14 days of each 21 day cycle for 6 cycles. Alternatively continuous intravenous infusion (CIV) 5-fluorouracil was administered at a dose of 800 mg/m<span class="Sup">2</span>/day from Day 1 through Day 5 every three weeks for 6 cycles.</p>
<p>The median age of the study population was 60 years (range: 21-83); 76% were male; 53% were Asian, 38% Caucasian, 5% Hispanic, 5% other racial/ethnic groups; 91% had ECOG PS of 0 or 1; 82% had primary gastric cancer and 18% had primary gastroesophageal adenocarcinoma.  Of these patients, 23% had undergone prior gastrectomy, 7% had received prior neoadjuvant and/or adjuvant therapy, and 2% had received prior radiotherapy.</p>
<p>The main outcome measure of Study 7 was overall survival (OS), analyzed by the unstratified log-rank test. The final OS analysis based on 351 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> was statistically significant (nominal significance level of 0.0193).  An updated OS analysis was conducted at one year after the final analysis. The efficacy results of both the final and the updated analyses are summarized in<a href="#table13"> Table 13 </a>and <a href="#figure7">Figure 7</a>.</p>
<a name="table13"></a><table width="100%">
<caption><span>Table 13: Study 7: Overall Survival in ITT Population</span></caption>
<col width="50%">
<col width="25%">
<col width="25%">
<thead><tr class="First Last">
<td class="Botrule Lrule" align="center" valign="bottom"> </td>
<td class="Botrule" align="center" valign="bottom">FC Arm<br>N=296</td>
<td class="Botrule Rrule" align="center" valign="bottom">FC + H Arm<br>N=298</td>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-40" href="#footnote-reference-40">*</a></dt>
<dd>Comparing with the nominal significance level of 0.0193.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Lrule Rrule" align="left" colspan="3" valign="bottom"><span class="Underline">Definitive (Second Interim) Overall Survival</span></td></tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      No. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> (%)</td>
<td align="center" valign="bottom">184 (62.2%)</td>
<td class="Rrule" align="center" valign="bottom">167 (56.0%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      Median</td>
<td align="center" valign="bottom">11.0</td>
<td class="Rrule" align="center" valign="bottom">13.5</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      95% CI (mos.)</td>
<td align="center" valign="bottom">(9.4, 12.5)</td>
<td class="Rrule" align="center" valign="bottom">(11.7, 15.7)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      Hazard Ratio</td>
<td class="Rrule" align="center" colspan="2" valign="bottom">0.73</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      95% CI</td>
<td class="Rrule" align="center" colspan="2" valign="bottom">(0.60, 0.91)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      p value<a name="footnote-reference-40" href="#footnote-40" class="Sup">*</a>, two sided</td>
<td class="Rrule" align="center" colspan="2" valign="bottom">0.0038</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="3" valign="bottom"><span class="Underline">Updated Overall Survival</span></td></tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      No. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> (%)</td>
<td align="center" valign="bottom">227 (76.7%)</td>
<td class="Rrule" align="center" valign="bottom">221 (74.2%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      Median</td>
<td align="center" valign="bottom">11.7</td>
<td class="Rrule" align="center" valign="bottom">13.1</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      95% CI (mos.)</td>
<td align="center" valign="bottom">(10.3, 13.0)</td>
<td class="Rrule" align="center" valign="bottom">(11.9, 15.1)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      Hazard Ratio</td>
<td class="Rrule" align="center" colspan="2" valign="bottom">0.80</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="bottom">      95% CI</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom">(0.67, 0.97)</td>
</tr>
</tbody>
</table>
<p><a name="figure7"></a><span class="Bold">Figure 7</span><br>Updated Overall Survival in Patients with Metastatic Gastric Cancer (Study 7)</p>
<p><img alt="Figure 7" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2&amp;name=herceptin-07.jpg"></p>
<p>An exploratory analysis of OS in patients based on HER2 gene amplification (FISH) and protein overexpression (IHC) testing is summarized in<a href="#table14"> Table 14</a>.</p>
<a name="table14"></a><table width="100%">
<caption><span>Table 14: Exploratory Analyses by HER2 Status using Updated Overall Survival Results</span></caption>
<col width="50%">
<col width="25%">
<col width="25%">
<thead><tr class="First Last">
<td class="Botrule Lrule" align="center" valign="bottom"> </td>
<td class="Botrule" align="center" valign="bottom">FC<br>(N=296)<a name="footnote-reference-41" href="#footnote-41" class="Sup">*</a>
</td>
<td class="Botrule Rrule" align="center" valign="bottom">FC + H<br>(N=298)<a name="footnote-reference-42" href="#footnote-42" class="Sup">†</a>
</td>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-41" href="#footnote-reference-41">*</a></dt>
<dd>Two patients on the FC arm who were FISH+ but IHC status unknown were excluded from the exploratory subgroup analyses.</dd>
<dt><a name="footnote-42" href="#footnote-reference-42">†</a></dt>
<dd>Five patients on the Herceptin-containing arm who were FISH+, but IHC status unknown were excluded from the exploratory subgroup analyses.</dd>
<dt><a name="footnote-43" href="#footnote-reference-43">‡</a></dt>
<dd>Includes 6 patients on chemotherapy arm, 10 patients on Herceptin arm with  FISH-, IHC3+ and 8 patients on chemotherapy arm, 8 patients on Herceptin arm with FISH status unknown, IHC 3+.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Lrule Rrule" align="left" colspan="3" valign="bottom"><span class="Underline">FISH+ / IHC 0, 1+ subgroup (N=133)</span></td></tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      No. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> / n (%)</td>
<td align="center" valign="bottom">57/71 (80%)</td>
<td class="Rrule" align="center" valign="bottom">56/62 (90%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      Median OS Duration (mos.)</td>
<td align="center" valign="bottom">8.8</td>
<td class="Rrule" align="center" valign="bottom">8.3</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      95% CI (mos.)</td>
<td align="center" valign="bottom">(6.4, 11.7)</td>
<td class="Rrule" align="center" valign="bottom">(6.2, 10.7)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      Hazard ratio (95% CI)</td>
<td class="Rrule" align="center" colspan="2" valign="bottom">1.33 (0.92, 1.92)</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="3" valign="bottom"><span class="Underline">FISH+ / IHC2+ subgroup (N=160)</span></td></tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      No. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> / n (%)</td>
<td align="center" valign="bottom">65/80 (81%)</td>
<td class="Rrule" align="center" valign="bottom">64/80 (80%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      Median OS Duration (mos.)</td>
<td align="center" valign="bottom">10.8</td>
<td class="Rrule" align="center" valign="bottom">12.3</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      95% CI (mos.)</td>
<td align="center" valign="bottom">(6.8, 12.8)</td>
<td class="Rrule" align="center" valign="bottom">(9.5, 15.7)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      Hazard ratio (95% CI)</td>
<td class="Rrule" align="center" colspan="2" valign="bottom">0.78 (0.55, 1.10)</td>
</tr>
<tr><td class="Lrule Rrule" align="left" colspan="3" valign="bottom"><span class="Underline">FISH+ or FISH /IHC3+<a name="footnote-reference-43" href="#footnote-43" class="Sup">‡</a> subgroup (N=294)</span></td></tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      No. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> / n (%)</td>
<td align="center" valign="bottom">104/143 (73%)</td>
<td class="Rrule" align="center" valign="bottom">96/151 (64%)</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      Median OS Duration (mos.)</td>
<td align="center" valign="bottom">13.2</td>
<td class="Rrule" align="center" valign="bottom">18.0</td>
</tr>
<tr>
<td class="Lrule" align="left" valign="bottom">      95% CI (mos.)</td>
<td align="center" valign="bottom">(11.5, 15.2)</td>
<td class="Rrule" align="center" valign="bottom">(15.5, 21.2)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="left" valign="bottom">      Hazard ratio (95% CI)</td>
<td class="Botrule Rrule" align="center" colspan="2" valign="bottom">0.66 (0.50, 0.87)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_00a91c26-66fe-4e68-b2f0-53b856bd4cd5"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ab8c029e-3228-4101-940e-3831fa45de06"></a><a name="section-14.1"></a><p></p>
<h2>16.1 How Supplied</h2>
<p class="First">Herceptin is supplied in a multi-use vial containing 440 mg trastuzumab as a lyophilized sterile powder, under vacuum. Each carton contains one vial Herceptin® and one vial (20 mL) of Bacteriostatic Water for Injection (BWFI), USP, containing 1.1% benzyl alcohol as a preservative. NDC 50242-134-68.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_a541dc17-0ec4-44c1-bd2a-92a01d873e5a"></a><a name="section-14.2"></a><p></p>
<h2>16.2 Stability and Storage</h2>
<p class="First">Vials of Herceptin are stable at 2–8°C (36–46°F) prior to reconstitution.</p>
<p>Do not use beyond the expiration date stamped on the vial. A vial of Herceptin reconstituted with BWFI, as supplied, is stable for 28 days after reconstitution when stored refrigerated at 2–8°C (36–46°F). Discard any remaining multi-dose reconstituted solution after 28 days. A vial of Herceptin reconstituted with unpreserved SWFI (not supplied) should be used immediately and any unused portion discarded. <span class="Bold">Do Not Freeze</span> Herceptin following reconstitution or dilution.</p>
<p>The solution of Herceptin for infusion diluted in polyvinylchloride or polyethylene bags containing 0.9% Sodium Chloride Injection, USP, should be stored at 2–8°C (36–46°F) for no more than 24 hours prior to use.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_463bfa68-510a-4653-9136-5d18fd68eb7c"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<ul>
<li>Advise patients to contact a health care professional immediately for any of the following: new onset or worsening <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the ankles/legs, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> of more than 5 pounds in 24 hours, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> <span class="Italics">[see Boxed Warning: <a href="#id_b641e93a-5973-4878-a5ec-04a065c9ff16"><span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">Cardiomyopathy</span></a>]</span>.</li>
<li>Advise pregnant women and females of reproductive potential that Herceptin exposure can result in fetal harm [<span class="Italics">see Use in Specific Populations (<a href="#i4i_pregnancy_ID_pregnancy">8.1</a>)</span>].</li>
<li>Advise women who are exposed to Herceptin during pregnancy or become pregnant within 7 months following the last dose of Herceptin, to immediately report exposure to the Genentech Adverse Event Line at 1-888-835-2555 [<span class="Italics">see <a href="#i4i_pregnancy_ID_pregnancy">Use in Specific Populations (8.1</a>, <a href="#S8.6">8.6)</a></span>].</li>
<li>Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Herceptin during pregnancy or within 7 months of conception.  To enroll the patient in the MotHER Pregnancy Registry call 1-800-690-6720 <span class="Italics">[see <a href="#i4i_pregnancy_ID_pregnancy">Use in Specific Populations (8.1)</a>]</span>.</li>
<li>Advise females of reproductive potential to avoid becoming pregnant while taking Herceptin.  If contraceptive methods are being considered, advise female patients to use effective contraception during treatment and for at least 7 months following the last dose of Herceptin <span class="Italics">[see <a href="#i4i_pregnancy_ID_pregnancy">Use in Specific Populations (8.1</a>, <a href="#S8.6">8.6)</a>]</span>.</li>
<li>Advise nursing mothers treated with Herceptin to discontinue nursing or discontinue Herceptin, taking into account the importance of the drug to the mother <span class="Italics">[see Use in Specific Populations (<a href="#i4i_nursing_mothers_id_8c61e7a4-c680-4eba-9ea1-c7069e448f96">8.3</a>)]</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0e02cd7b-33f7-4642-ad68-69eca6873ca5"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">HERCEPTIN<span class="Sup">®</span> [trastuzumab]</span></p>
<p>Manufactured by:<br>Genentech, Inc.<br><span class="Bold">A Member of the Roche Group</span><br>1 DNA Way<br>South San Francisco, CA 94080-4990</p>
<p>Herceptin® is a registered trademark of Genentech, Inc.<br><span class="Sup">©</span>2015 Genentech, Inc.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_363d1693-7423-4052-bf7b-a959a5d61463"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - Kit Carton</h1>
<p class="First">NDC 50242-134-68<br>Multi-dose Vial</p>
<p><span class="Bold">Herceptin</span><span class="Sup">®</span><br>trastuzumab</p>
<p><span class="Bold">440 mg</span></p>
<p><span class="Bold">KEEP REFRIGERATED<br>Rx only</span></p>
<p>10136466</p>
<p><span class="Bold">Genentech</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - Kit Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2&amp;name=herceptin-08.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HERCEPTIN 		
					</strong><br><span class="contentTableReg">trastuzumab kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50242-134</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50242-134-68</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, MULTI-DOSE </td>
<td class="formItem">20 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">20 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>HERCEPTIN 		
					</strong><br><span class="contentTableReg">trastuzumab injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>TRASTUZUMAB</strong> (TRASTUZUMAB) </td>
<td class="formItem">TRASTUZUMAB</td>
<td class="formItem">440 mg  in 20 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TREHALOSE DIHYDRATE</strong></td>
<td class="formItem">400 mg  in 20 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HISTIDINE MONOHYDROCHLORIDE</strong></td>
<td class="formItem">9.9 mg  in 20 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HISTIDINE</strong></td>
<td class="formItem">6.4 mg  in 20 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 20</strong></td>
<td class="formItem">1.8 mg  in 20 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL, MULTI-DOSE; Combination Product Type = C102834</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103792</td>
<td class="formItem">09/25/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>BACTERIOSTATIC WATER 		
					</strong><br><span class="contentTableReg">water solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZYL ALCOHOL</strong></td>
<td class="formItem">11 mg  in 20 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL; Combination Product Type = C102834</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103792</td>
<td class="formItem">09/25/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103792</td>
<td class="formItem">09/25/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Genentech, Inc.
							(080129000)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Genentech, Inc. (080129000)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genentech, Inc. (SSF)</td>
<td class="formItem"></td>
<td class="formItem">080129000</td>
<td class="formItem">MANUFACTURE(50242-134), ANALYSIS(50242-134)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genentech, Inc. (Vacaville)</td>
<td class="formItem"></td>
<td class="formItem">004074162</td>
<td class="formItem">ANALYSIS(50242-134), API MANUFACTURE(50242-134)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Roche Singapore Technical Operations Pte. Ltd.</td>
<td class="formItem"></td>
<td class="formItem">937189173</td>
<td class="formItem">API MANUFACTURE(50242-134), ANALYSIS(50242-134)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Roche Diagnostics GmbH</td>
<td class="formItem"></td>
<td class="formItem">323105205</td>
<td class="formItem">API MANUFACTURE(50242-134), ANALYSIS(50242-134)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genentech, Inc. (Hillsboro)</td>
<td class="formItem"></td>
<td class="formItem">833220176</td>
<td class="formItem">MANUFACTURE(50242-134), PACK(50242-134)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Genentech, Inc. (Oceanside)</td>
<td class="formItem"></td>
<td class="formItem">146373191</td>
<td class="formItem">ANALYSIS(50242-134)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c5c82a2e-4f78-4ac1-92fe-725c1ea74958</div>
<div>Set id: 492dbdb2-077e-4064-bff3-372d6af0a7a2</div>
<div>Version: 7</div>
<div>Effective Time: 20150429</div>
</div>
</div> <div class="DistributorName">Genentech, Inc.</div></p>
</body></html>
